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Abstract 
Hepatocyte damage caused by genetic and acquired defects in mitochondria can result 
in severe liver dysfunction causing disease and death. Mammalian hepatocytes 
possess specific receptors on their surfaces called asialoglycoprotein receptors 
(AsGRs), which can recognize and bind asialoglycoproteins (AsGs).  After binding, 
AsGs are internalized by receptor-mediated endocytosis within membrane-limited 
vesicles, endosomes, which ultimately fuse with lysosomes resulting in degradation. 
This pathway represents a natural mechanism by which substances outside cells can 
gain access to the interior of liver cells. In the past, small molecules have been bound to 
AsGs to deliver them specifically to the liver. The aim of this study was to determine 
whether AsGs could serve as targetable carriers for mitochondria to permit targeting 
specifically to hepatocytes by the AsGR pathway. We describe here, a method by which 
mitochondria can be coated with AsGs by a non-damaging interaction. We converted an 
AsG into a highly positively charged molecule, and took advantage of the fact that the 
surface of mitochondria is negatively charged. By mixing a positively charged AsG 
protein conjugate with mitochondria, the conjugate could bind to mitochondria in a 
strong, but non-damaging electrostatic (charge-charge) interaction forming protein–
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specifically by hepatocytes. We have also developed a method by which AsGs–
mitochondria complexes can be released from endosomes. This allows escape from 
endosomes before lysosomal digestion and cytoplasmic delivery of healthy 
mitochondria to the cells. The system can result in rescue of cells rendered 
mitochondria-free by drug toxicity, and proliferation of both host cells and transplanted 
mitochondria. Currently, there is no treatment for mitochondrial dysfunction, and no 
means to repair or replace damaged mitochondria. Targeting healthy mitochondria to 
hepatocytes with defective or damaged mitochondria by the AsGR pathway would be 
expected to confer on those cells a selective survival advantage. As a result, those cells 
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CHAPTER 1: INTRODUCTION 
MITOCHONDRIA 
Mitochondria are intracellular organelles that are involved in energy generation [1], 
signaling [2, 3], cellular differentiation [4-6] and cell death [7-10]. Because they are 
primary source of generating ATP, mitochondria are considered the metabolic 
powerhouses of mammalian cells [1]. Mitochondria also play an essential role in 
maintaining the high energy needs of certain organs such as the liver, which has more 
mitochondria per cell than most other cell types like small lymphocytes [11].   
 
MITOCHONDRIAL STRUCTURE 
Mitochondria are unique among intracellular organelles in that their surface consists of 
an outer and inner membrane. The membranes differ from each other in composition, 
properties, and function [1]. However, one essential characteristic that they have in 
common is that the integrity of inner and outer membranes must be maintained for their 
proper functions. This membrane integrity is strictly regulated through interactions 
between various cellular proteins [12]. The basic structure of the mitochondrial 
membranes is similar to the cell membranes. It consists of a lipid bilayer with two sheets 
of phospholipids such that hydrophilic phosphate heads point out on either side of the 
bilayer and the hydrophobic tails point in towards the core of the bilayer. Several 
integral proteins and cholesterol [13] are associated with these lipid bilayers to act as 




phospholipid composition of outer membrane of mitochondria differs from that of other 
membranes [14]. It also contains porins, which are integral membrane proteins, that 
allow large molecules to freely diffuse across the membrane [15]. Proteins such as 
translocase on the outer membrane are involved in the active transport of larger 
proteins across the membrane [16]. Some essential mitochondrial outer membrane 
proteins like TOM20 and TOM22 result in a negatively charged outer membrane of 
mitochondria [17, 18]. The inner mitochondrial membrane is extensively folded into 
cristae, which increase the total membrane surface area compared to outer membrane 
[19]. The lipid composition of inner membrane is similar to bacterial membranes 
characterized by low levels of triglycerides causing increased unsaturation [20]. It is 
freely permeable to oxygen, carbon dioxide, and water and is associated with several 
essential proteins and enzymes, which are involved with aerobic respiration [21].  
Together these proteins constitute the respiratory complex of mitochondria, which takes 
part in synthesis of ATP by mitochondria [22]. The inner and outer membranes result in 
the creation of 2 compartments in the mitochondria called inter-membrane space and 
inner matrix. 
 
MORPHOLOGICAL DYNAMICS OF MITOCHONDRIA 
In spite of their size and complexity, mitochondria are highly dynamic and change size 
and shape frequently by processes of fusion, fission and movement across the 
cytoskeletal structure [23]. Frequent fusion and fission of mitochondria in cells provide 




through exchange of mitochondrial genomes between fusing mitochondria. As a result, 
mitochondria morphologically can be highly polymorphic [24] and function independently 
within cells [25]. A group of proteins play a role in regulating morphological remodeling 
of mitochondria [26]. Some proteins like Drp1/Dnm1 [27, 28] or Fis1/Mdv2 [29] localized 
on outer membrane of mitochondria regulate fission of mitochondria. Once initiated, 
fission of mitochondria takes place in approximately 3 hours [30]. Other proteins like 
Mgm1/OPA1 [31, 32] and Fzo1p/Mfn 1&2 [33] localized on inner or outer membrane of 
mitochondria regulate fusion of mitochondria.  
 
THE MITOCHONDRIAL GENOME 
Human mitochondrial DNA is approximately 16,600 base pairs long, and codes for 37 
genes [34, 35] which includes 13 genes for subunits of respiratory complexes, 22 for 
mitochondrial tRNA, and 2 for rRNA [36]. Most of the essential structural and functional 
proteins of mitochondria are expressed from the cell nucleus, and are transported to 
mitochondria. Therefore, mitochondrial proteins are encoded from genomes that 
originate from two distinct sources, the nucleus and the mitochondria itself.  Each 
mitochondrion contains 5-12 copies of DNA, which is circular and double-stranded [37]. 
Mitochondria have their own DNA replication machinery enclosed in inner membrane 
compartment, which allows them to replicate independent of cell nuclear DNA division. 
Unlike cell nuclear DNA polymerase which has a proof-reading exonuclease 
mechanism [38], mitochondrial DNA polymerase lack these nucleotide excision repair 




replication process or damage by radiation or chemicals [40]. Although other types of 
mitochondrial DNA repair pathways, such as base excision repair [41], have been 
reported, increased damage to mitochondrial DNA due to close proximity to reactive 
oxygen species generated by electron transport chain on inner membrane of 
mitochondria and lack of other proof reading and editing pathways leads to 
accumulations of mutations in mitochondrial DNA, and give rise to heteroplasmic (a 
mixture of non-uniform collection of mitochondrial DNA with normal or mutated DNA 
sequences) mitochondrial DNA [42]. Severe mutations can lead to cell, organ, and 
organism death. However, milder mutations can permit survival, but abnormalities are 
defined by possible mitochondrial dysfunction [43]. The proportion of mutations 
accumulated in mitochondrial DNA molecules determines both the penetrance and 
severity of expression of some mitochondrial diseases. Mitochondria divide during cell 
division, and also independent of cell division primarily in response to the energy needs 
of the cell [1, 44]. Introduction of normal mitochondrial DNA to mitochondria containing 
mutated DNA by dynamic networking provides an efficient mechanism of mitochondrial 
repair [45]. Since mitochondria are sorted randomly among daughter cells during cell 
division, each daughter cell can receive different proportions of mitochondria carrying 
normal and mutant mitochondrial DNA. Mitochondrial DNA sequence heteroplasmy can 
also be used to determine lineages [46]. 
Despite the rearrangement of genes, comparison of mitochondrial DNA sequences in 
different species show high levels of homology. Mitochondrial DNA sequences from 
different species can be distinguished from each other based on non-homologous and 




MITOCHONDRIAL REGULATION OF CELL APOPTOSIS 
Apoptosis, programmed cell death, provides a defense mechanism by which unwanted 
and potentially dangerous cells are eliminated and cell number regulated [48]. 
Apoptosis is under tight control of several protein families and signaling cascades. 
Proteolytic activity of the caspase protein family plays a major role in apoptosis [49].  
Biochemical studies have identified numerous mitochondrial proteins that have a 
complex role in activating cellular apoptotic programs directly [50, 51]. Permeabilization 
of the outer membrane of mitochondria triggers the activation of the caspase proteases. 
Release of various pro-apoptotic proteins from inter-membrane space of mitochondria, 
such as cytochrome c, promotes caspase activation [52]. Consequently, the integrity of 
the outer membranes of mitochondria is highly regulated through interactions between 
several pro- and anti-apoptotic proteins in cells [7, 53]. Damage to the outer membranes 
of mitochondria also leads to mitochondrial dysfunction and usually causes cell death 
regardless of the activity of caspase proteases.  
 
MITOCHONDRIAL DYSFUNCTIONAL DISEASES 
Dysfunction of mitochondria has been recognized as an important contributor to an 
array of human diseases including hepatic mitochondrial disorders [54, 55], cardiac 
dysfunction [56] and autism [57]. Mutations in both nuclear and mitochondrial genomes 
encoding mitochondrial proteins can cause mitochondrial dysfunction [58]. Many factors 
including a threshold effect, and segregation and clonal expansion govern the 




increases with aging, normal mitochondrial DNA in cells allow mitochondria to function 
properly until a threshold level is reached where the ratio of mutated mitochondrial DNA 
increases significantly compared to normal mitochondrial DNA. At this point, clinical 
symptoms of mitochondrial dysfunction start to appear [59]. While the segregation of 
mitochondria into two daughter cells is usually random, if a mutant load in a specific cell 
type exceeds the pathogenic threshold, clinical indicators of mitochondrial disorders can 
appear [60]. In addition, clonal expansion of specific mutated mitochondrial DNA 
molecules in cells can cause increased risk for the development of mitochondrial 
disorders [61, 62].  
Many types of mutations are possible in mitochondrial DNA. Point mutations may occur 
in protein-coding genes during mitochondrial DNA replication, and can cause major 
mitochondrial functional defects. Although mitochondria are heteroplasmic, these 
mutations tend to be recessive. However, if levels of mutations increase beyond 
threshold levels, these mutations can have a deleterious effect on mitochondrial 
functions [63-65]. Another type of mitochondrial DNA mutation is large-scale deletions 
and rearrangements of DNA [66]. An exponential accumulation of such deletions has 
been reported in aged tissues and in individuals with neurodegenerative diseases [67, 
68].  Because mitochondria are sorted randomly among daughter cells during cell 
division, each daughter cell can receive different proportions of mitochondria carrying 
normal and mutant mitochondrial DNA. A database compiling the description of all 
known pathogenic mitochondrial DNA mutations is under construction [58].  
Population-based studies have shown that mitochondrial disorders are relatively 




over-representation of specific mitochondrial DNA disorders [70]. Studies on childhood 
and adult mitochondrial disorders suggests that prevalence is at least 1 in 5000, and 
could be much higher [71]. Genetic and clinical manifestations of mitochondrial 
disorders increase with aging because of accumulation of mitochondrial mutations [72]. 
However, the age of onset depends on levels of mutations accumulated and the 
severity of the biochemical defect caused by mutations [73, 74]. Other nuclear genetic 
or environmental factors also play a role in expression of disease. The clinical 
symptoms associated with mitochondrial DNA mutations are extremely variable and can 
occur at any stage in life [75]. There is clear evidence supporting the involvement of 
mitochondrial DNA mutations in aging, neurodegeneration, and tumorigenesis [76]. 
Figure 1.1 shows some of the mitochondrial DNA mutations that are associated with 
human mitochondrial disorders. Some mitochondrial diseases have an early onset 
starting in infants or young children, example Leigh syndrome [77], Kearns–Sayre 
syndrome (KSS) [78], and Depletion syndrome (found in various organs depending on 
tissues which have mitochondrial DNA depletion, resulting in muscle weakness, 
progressive encephalopathy or liver failure [79]. Organ transplantation can be an 
effective therapeutic approach in these patients if suffering from a specific tissue defect. 
Mitochondrial disorders affecting the central nervous system usually manifest in late 
childhood or adult life with clinical syndromes including mitochondrial encephalopathy, 
lactic acidosis, stroke-like episodes [80, 81], chronic progressive external 
ophthalmoplegia [59], neuropathy, ataxia, retinitis pigmentosa [82], Leber's hereditary 
optic neuropathy [83, 84], myoclonic epilepsy and ragged red fibers [85]. Mitochondrial 




inheritance of mitochondrial DNA defects, damage to the mitochondria can also be 
caused by environmental factors [86]. Several toxic substances internalized by cells can 
cause direct damage to mitochondria and result in cell death. 
Instead of size and location of deletions, the levels and tissue distribution of deleted 
mitochondrial DNA are more important factors in determining clinical syndromes [87]. In 
most cases, mutations in mitochondrial DNA impair mitochondrial function, depriving the 
cell its main source of energy required for its optimal function. As a result, cell function 
is impaired or it causes cell death, which compromises tissue or organ function and 
leads to disease.  
 
DIAGNOSIS AND TREATMENT OF MITOCHONDRIAL DYSFUNCTIONAL 
DISORDERS  
Lack of clear correlation between mitochondrial DNA genotype and disorder phenotype 
makes the diagnosis of mitochondrial DNA disorders complicated. Clinically, family 
history and histological changes are helpful to diagnose mitochondrial disease, but 
these are not always clear. Development of rational diagnostic algorithms has improved 
over time with help of molecular testing supported by histochemical, and biochemical 
testing [88].  
A few key histochemical and molecular approaches currently are being used to 
diagnose mitochondrial genetic disorders are as follows: 
Histochemical and biochemical testing: Some patients show specific histological and 




dysfunction. Appearance of ragged-fiber like structures in tissues reflects the 
accumulation of defective mitochondria with cytochrome c oxidase abnormalities. 
Cytochrome c oxidase is an essential enzyme found on inner membrane of 
mitochondria which takes part in the synthesis of ATP by mitochondria [89]. 
Abnormalities in cytochrome c oxidase can cause severe metabolic disorders. 
Cytochrome c oxidase contains subunits encoded by both nuclear and mitochondrial 
genomes, and the appearance of ragged-fiber like structures in tissues suggests 
mitochondrial DNA involvement. However, this histological finding is of limited use 
because tissue biopsies from patients with known mitochondrial DNA mutations, for 
example a MELAS phenotype, have shown no distinct fiber-like structures [90].   
Determination of enzyme activities involved in respiratory function of mitochondria from 
clinically affected tissue [91] is often used to diagnose mitochondrial disorders. Oxygen 
consumption and ATP synthesis by intact organelles from affected tissue also helps to 
determine the type of mitochondrial dysfunction [92]. The identification of specific 
mitochondrial enzyme abnormalities can help to identify the specific molecular genetic 
defect. 
Molecular genetic testing: Mitochondrial DNA point mutations, deletions and 
rearrangements can be assayed by Southern blotting [93, 94], PCR or sequencing [95, 
96]. Determination of quantitative loss of normal mitochondrial DNA or accumulation of 
defective mitochondrial DNA by real-time PCR has been a good indicator of 
mitochondrial disorders. Several known genes have been implicated in myopathic or 
hepatocerebral disorders. Because of its small size, screening the entire mitochondrial 




electrophoresis [97] and denaturing high-performance liquid chromatography [98] and 
several new emerging technologies such as microarrays [99] have proven very useful. 
Given the highly heteroplasmic nature of mitochondrial DNA, careful assessment of 
newly identified mutations and variations is required to establish the association with 
human diseases. 
Although several guidelines to establish a novel mitochondrial DNA variant as 
pathogenic have been proposed [58] and some have been applied in clinical studies 
[100], more canonical criteria are required to accurately identify new variations 
associated with human mitochondrial disorders. 
Treatment Strategies: Despite an increased understanding of mitochondrial genetics 
and function, and pathogenesis of mitochondrial DNA variations, currently no effective 
treatment options are available, except cases where transplant surgery might be helpful. 
Treatments with vitamins, cofactors, metabolites or electron acceptors to bypass 
respiratory complex defects have been attempted, but have not been very successful 
(227). Currently more focused and disease-specific treatments are under investigation.  
Exercise therapy: Exercise therapy aims to improve physical capacity and quality of life 
in patients who have myopathy caused by mitochondrial DNA variations. Although it 
does not cause any significant change in mutations in mitochondrial DNA, clinical 
studies have shown improved mitochondrial function [101]. Muscle training studies in 
mice have shown enhanced ATP levels, delayed disease onset, and increased life 
expectancy [102]. Effects of long-term training on mitochondrial DNA mutation load are 




undifferentiated myogenic cells in response to injury caused by resistance exercise is 
also under study. Activation of undifferentiated myogenic cells containing normal 
mitochondria into muscle tissue of patients with high levels of sporadically mutated 
mitochondrial DNA in mature muscle could shift heteroplasmy levels towards healthy 
mitochondrial genome, and may help to recover muscular function [103]. Although 
further studies are required to determine the optimal parameters for an exercise regime, 
this method has been found to be clinically useful to some extent [104]. 
Gene therapy: Shifting the balance of mutant to normal mitochondrial genome can help 
in manipulating heteroplasmy levels in mitochondria and may prove to be useful for 
treatment of mitochondrial disorders. Genetic-based strategies to inhibit the replication 
of mutated mitochondrial DNA and hence allowing normal mitochondrial genome to 
propagate are under investigation [105]. This can be accomplished by transferring 
interfering molecules into the mitochondria. A major obstacle in these strategies is 
transport of molecules across the two mitochondrial membranes. However, 
investigations are under way to establish the ability of such molecules to enter 
mitochondria to inhibit mutated mitochondria DNA replication and their effectiveness in 
vivo. 
Alternatively restriction endonucleases capable of distinguishing between mutated and 
normal mitochondrial genomes have also been used. This approach may be limited to 
such mutations that would give rise to additional restriction sites [106]. Selective 
targeting of mutated mitochondrial DNA can also be attempted with targeted zinc finger 




in cells, in a sequence-specific manner [107]. This strategy may also be limited by 
targeted transfection and successful expression in defective tissues. 
The expression of mitochondrial genes in the nucleus to compensate for mutated genes 
in mitochondrial DNA causing functional defects in mitochondria can also be helpful to 
recover respiratory defects of mitochondria [108]. Studies of mitochondrial localization 
of such expressions from nucleus are under investigation [109]. Recently a mechanism 
to import cytosolic tRNA to mitochondria has been demonstrated [110] which can help 
in the development of future therapies for mitochondrial DNA mutations causing defects 
in genes expressing mitochondrial tRNAs. Overall, current investigations towards the 
development of successful gene therapies for the treatment of mitochondrial 
dysfunctional disorders are encouraging. 
Implantation of reprogrammed cells derived from patients with heteroplasmic mutations 
in mitochondrial DNA is another potential treatment under investigation [111]. Induced 
pluripotent stem cells (iPSC) displaying normal mitochondrial functions can be screened 
from a population of iPSCs derived from affected patients. Generation of pluripotent 
cells by replacing nuclear DNA of the egg with nuclear DNA of the diseases somatic 
cells (somatic cell nuclear transfer) and thus, containing healthy mitochondria and 
nucleus, is another method to obtain potential cells that can be used to correct 
mitochondrial disorders.  
The rates of transmission of mitochondrial DNA mutations from mother to offspring vary 
considerably [112]. This makes genetic counseling extremely challenging. Though 




major clinical concern is whether heteroplasmy levels would reflect phenotypic 
outcomes at other fetal tissue levels [113]. Studies in heteroplasmic mice have shown 
that transfer of the pronuclei from a fertilized zygote of a female mouse with 
mitochondrial DNA disease to an enucleated zygote from a healthy donor female has 
successfully produced healthy offspring [114]. In addition, the United Kingdom has 
approved a gene-therapy technique, which involves transferring the nucleus from a 
human female egg to a donor enucleated egg with healthy mitochondria and then 
fertilizing the donor egg [115-117]. 
Moreover, in spite of significant progress in understanding and documenting 
mitochondrial DNA defects responsible for the development of mitochondrial 
dysfunction, the diagnosis of disorders is challenging due to increasing numbers of 
reported pathogenic mutations and constantly evolving rules of pathogenicity. Although 
implementation of high-throughput screening approaches has improved the situation, 
the lack of effective treatments has been disappointing. New experimental approaches 
under investigation are promising for mitochondrial DNA disease treatment. In addition 
to this, recent research strategies focused on elucidating the molecular mechanisms of 
disease and complex relationships between mitochondrial DNA variations and their 
diverse clinical phenotypes have been helpful in developing therapies for these 
disorders. Further progress in understanding the pathogenesis of specific mitochondrial 
disorders will be necessary to uncover novel targets or molecular pathways that may be 
exploited for developing therapies. In the meantime, approaches to develop generic 





MITOCHONDRIAL HEPATOPATHIES  
Because of their high metabolic activity, hepatocytes require, and contain the highest 
density of mitochondria of all human cell types [37]. Consequently, hepatocytes are also 
more susceptible to disorders that affect mitochondria [118]. Mitochondrial 
hepatopathies can be inherited as a mitochondrial genetic defect or acquired due to 
alcohol or drug injury to cells. 
Disorders affecting mitochondrial function would directly affect hepatocellular 
metabolism resulting in impaired liver function, steatosis and cell death. Clinically, 
genetic and more commonly drug- and alcohol-induced mitochondrial damage has been 
shown to cause severe liver disease, which ultimately leads to liver failure and death 
[119, 120]. Current medical treatments available for mitochondrial hepatopathies are 
largely ineffective, and their diagnosis is difficult because of lack of distinct clinical 
symptoms. However, several specific molecular defects (including mutations, deletion or 
rearrangement of mitochondrial DNA) have been identified in recent years.  
GENETIC MITOCHONDRIAL DISORDERS OF LIVER 
Clinically, mitochondrial hepatopathies have varied manifestations that include acute or 
chronic liver failure, lactic acidosis, and cholestasis. Below are few examples of primary 
hepatopathies caused by mitochondrial defects: 
Neonatal Liver Failure: Acute liver failure that occurs in infants who are only a few 
weeks to a few months old is due to respiratory chain defects [121]. This is caused by 
defective mitochondrial genes encoded by the nuclear genome. This disease 




Mitochondrial DNA depletion syndrome: This syndrome is due to decreased 
mitochondrial DNA copy number resulting into insufficient expression of mitochondrial 
genes from mitochondrial DNA [122]. Patients present with myopathy, hepatomegaly 
and progressive liver failure causes death at an early age. 
Alpers-Huttenlocher Syndrome (Delayed-Onset Liver Disease): This is caused by 
defective expression of mitochondrial genes in nuclear DNA. Disease is characterized 
by hepatomegaly, jaundice, and progressive coagulopathy and hypoglycemia [123]. 
Onset of symptoms occurs between 2 months to 8 years of life. 
Pearson's Syndrome: In this syndrome, multi organ system failure (hematopoietic 
system, exocrine pancreas, liver, and kidneys) occurs due to mitochondrial DNA 
depletion and rearrangement defects. Liver failure and death has been reported before 
the age of 4 years [124]. 
Villous Atrophy Syndrome: Caused by deletion in mitochondrial DNA resulting in 
respiratory dysfunction [125]. Symptoms are severe anorexia, vomiting, chronic 
diarrhea, and villus atrophy in the first year of life. Hepatic involvement is characterized 
by mild elevation of aminotransferases, hepatomegaly, and steatosis.  
Navajo Neurohepatopathy: Caused by rearrangement in mitochondrial DNA resulting in 
intra-cellular respiratory dysfunction [126]. Clinical symptoms are cholestasis and 
cirrhosis. Liver failure may occur in infancy or childhood.  
Currently various vitamins, cofactors, respiratory substrates, or antioxidant compounds 
are being used to by-pass the damage to the respiratory function of cells [127-129]. 




Because of involvement of other organ systems, advantages of liver transplantation are 
also speculative [131, 132]. Despite extensive research on genetic mitochondrial 
hepatopathies in recent years, much remains to be learned about these disorders. 
ACQUIRED MITOCHONDRIAL DISORDERS OF LIVER 
Besides genetic mitochondrial hepatopathies, mitochondrial injuries in liver cells can 
also be acquired by exposure to alcohol and drugs. [120]. Since detoxification of most 
drugs takes place in the liver, hepatocytes are susceptible to adverse effects of these 
drugs. This poses a major issue for pharmaceutical companies because it causes 
failure of a drug during development phase or withdrawal of an already marketed 
medicine [119]. Although hepatotoxicity can be induced in different ways [133], 
mitochondrial dysfunction is a common mechanism of injury [134]. Deleterious effects of 
drugs on hepatic mitochondria can disturb mitochondrial respiratory functions or affect 
mitochondrial DNA. By blocking mitochondrial respiratory function, damaging 
mitochondrial membranes and causing pro-apoptotic proteins to leak into the cytoplasm 
or triggering mitochondrial DNA mutations, drugs can cause necrosis or apoptosis of 
hepatocytes, which can lead to liver cirrhosis or failure [134]. Depending on 
susceptibility, various hepatic conditions as microvesicular steatosis, lesions, 
hypoglycaemia hyperlactataemia, lactic acidosis, myopathy, rhabdomyolysis, 
pancreatitis, peripheral neuropathy or lipoatrophy can occur [135, 136]. Severe liver 
injury caused by mitochondrial dysfunction in clinical trials can be avoided by careful 
studies of newly developed drugs during the preclinical safety studies. 





Induction of mitochondrial outer membrane damage and release of pro-apoptotic 
proteins: Several drugs cause damage to outer membrane of mitochondria, which leads 
to release of pro-apoptotic proteins, such as cytochrome c, into cytoplasm, initiating 
apoptosis pathways resulting in cell death. Extensive liver cell death can lead to liver 
failure. For example, acetaminophen, valproic acid, salicylic acid and others have been 
shown to cause fulminant hepatic failure [137, 138]. The molecular mechanisms of 
induction of mitochondrial membrane damage by drugs are still poorly understood. 
Release of pro-apoptotic proteins from mitochondria can also be induced indirectly by 
translocation of proteins from inter-membrane space to cytoplasm [139]. 
Impairment of respiration enzymes: Some drugs can act as mitochondrial poisons by 
directly impairing one or more mitochondrial enzyme involved in respiration process to 
produce ATP [140]. Higher intra-mitochondrial accumulation of drugs like amiodarone, 
perhexiline or tamoxifen causes progressive decrease in mitochondrial respiration [140, 
141]. This leads to a decrease in ATP production in cells [142]. 
Several drugs can impair other function of mitochondria, such as fatty acid oxidation 
impairment [143]. Others can cause more than one kind of damage to mitochondria in 
cells [134]. 
Mitochondrial DNA depletion or mutation: Nucleoside based anti-viral drugs have shown 
to either inhibit mitochondrial DNA replication directly by inhibiting mitochondrial DNA 
polymerase as in case of fialuridine (FIAU) [144]) or by incorporation into growing chain 
of mitochondria and immediately terminating the replication as in case of stavudine 




mitochondrial DNA replication resulting in point mutations or deletions/rearrangements 
in mitochondrial DNA. 
Environmental factors can also enhance the risk of drug-induced mitochondrial 
dysfunction [146, 147]. Alcohol abuse have shown to induce underlying mitochondrial 
dysfunctions, which may render the liver more susceptible to drug-induced 
mitochondrial disorder [148]. Some microsomal enzyme inducers or viral infections may 
also act as predisposing factor to drug-induced mitochondrial dysfunction in the liver 
[149, 150]. Release of viral proteins, cytokines and interferons can affect mitochondrial 
function and disturb intracellular homeostasis that can have additive effects to drug 
induced mitochondrial dysfunction [135]. 
Although exercise therapies and gene therapies are extensively being studied, effective 






The liver is the largest and one of most important organs of human body and is located 
on upper-right portion of the abdominal cavity [151]. In humans, the liver consists of four 
lobes. Because of its complexity, no other organ or artificial device can reproduce all the 
functions of the liver [152]. The liver is a highly specialized organ consisting of four 
major cell types; parenchymal hepatocytes, stellate cells, sinusoidal endothelial cells 
and Kupffer cells [153]. Among these, hepatocytes form 80% of liver cytoplasmic mass, 
and are responsible for the majority of physiological functions of liver. 
The liver has rich blood supply, receiving blood from the hepatic portal vein and hepatic 
arteries. Seventy-five percent of the blood supply to the liver is delivered by hepatic 
portal vein which carries venous blood drained from the spleen, gastrointestinal tract, 
and its associated organs [154]. Unlike most veins, the hepatic portal vein does not 
drain into the heart [155]. Instead it delivers venous blood into another liver 
microvascular system, namely the hepatic sinusoids of the liver [156]. Blood from the 
gastrointestinal tract reaching liver by hepatic portal vein supplies the liver with 
absorbed nutrients and toxins from intestines and allows the liver to process nutrients 
and detoxify ingested toxins or drugs [157]. The hepatic arteries supply arterial blood to 
the liver, which accounts for rest of 25% of liver blood flow. Oxygen demands of the liver 
are met by both sources of blood supply, but mostly from the hepatic artery. Blood from 
hepatic artery and portal vein flows into low-pressure vascular channels called sinusoids 
[158, 159]. Sinusoids are lined with highly fenestrated endothelial cells which allow free 
flow of plasma from sinusoidal blood into the space between hepatocytes and 




plasma brought by blood and excretes waste or detoxified materials into it [161]. 
Hepatocytes are involved in a wide variety of biochemical reactions, including the 
synthesis and breakdown of molecules. Hepatocytes are also involved in other 
functions, including detoxification of various metabolites and drugs (modification, and 
excretion of exogenous and endogenous toxic substances) [162], protein synthesis, 
nutrient storage and production of several bio-chemicals required for digestion. 
Hepatocytes also play a major role in metabolism including regulation of glycogen 
storage, hormone production and plasma protein synthesis.  
Hepatic sinusoids are also populated by numerous Kupffer cells for phagocytosis of 
harmful particles carried to the liver through blood [163]. Kupffer cells are the resident 
liver macrophages acting as scavenger cells, responsible for removing unwanted 
particulate material from the liver circulation [164]. However, studies indicate that 
Kupffer cells may also be involved in the pathogenesis of various liver diseases [165]. 
Kupffer cells may cause destruction of hepatocytes by producing harmful soluble 
mediators [166] or fibrosis by production of cytokines that lead to the transformation of 
stellate cells into myofibroblasts [167]. Kupffer cells have also been implicated in 
alcohol-induced injury to liver [168].  
Stellate (fat storing cells) in liver have been shown to be the source of fibrosis which 
occurs in response to chronic liver injury [169]. Activation of these stellate cells converts 
them to myofibroblasts producing excess extracellular matrix, [170] and reducing the 
flow of blood through sinusoids [159] which are lined with specialized endothelial cells 
[160]. These latter cells are involved in determining which solutes are filtered and can 




The liver plays a crucial role in detoxification of substances, including alcohol, drugs, 
pesticides, and heavy metals, that are harmful for body [171]. Exposure to higher levels 
of these substances can overwhelm the liver, resulting in liver failure [172]. Toxins are 
primarily delivered to the liver by the portal vein where they are processed and 
excreted. Toxic byproducts of normal metabolism (e.g. ammonia) and excess hormones 
(e.g. estrogen) are also processed in liver. Many drugs, including acetaminophen, anti-
HIV/HCV drugs, and herbal drugs are also processed by the liver and can cause severe 
liver damage [120, 145, 172].  Damaged liver may not adequately process these toxic 
substances, which potentially could lead to dangerously high toxin levels in blood and 
significant side effects [173, 174]. 
METABOLIC DETOXIFICATION BY THE LIVER 
Detoxification refers to a specific metabolic pathway that processes unwanted 
substances for elimination. It involves a series of enzymatic reactions that results in 
neutralization and solubilization of toxins, and recycling or transportation to secretory 
organs (like kidneys), for excretion from the body [175]. Endogenously-produced 
substances such as inflammatory molecules, excess hormones, vitamins, and signaling 
compounds are eliminated by the same detoxification systems that protect the body 
from environmental toxins or clear drugs and toxins from blood circulation and helps in 
homeostatic balance in the body. Unprocessed toxins may act as mutagens causing 
DNA damage or mutations, carcinogens or disrupt other metabolic pathways resulting in 





Detoxification can be divided into three phases. 
Phase I: Enzymatic transformation: The metabolic detoxification systems enzymatically 
transform lipid-soluble compounds into water soluble compounds by conjugating water-
soluble molecules to the lipid-soluble toxins to increase solubilization of toxins for next 
phase of detoxification [178]. Following the solubilization, some modified toxins can be 
transported out of the cell and excreted directly. 
Phase II: Enzymatic conjugation: Transformed toxin in phase l of detoxification may still 
be unsuitable for immediate elimination from the cell. This can be because of insufficient 
water-solubility of molecules even after phase I reactions to complete the entire 
excretion pathway or products from the phase I reactions are more reactive than the 
original toxins and that can potentially be more destructive. Activities of the phase II 
enzymes increase solubility and reduce toxicity of phase I products. Phase II enzymes 
are also responsible for anti-mutagenic and anti-carcinogenic properties of the 
metabolic detoxification systems [179, 180]. 
Phase III: Transport: Phase III transporters actively pump out neutralized toxins that 
require specific transporters to move in and out of cells through the cell membrane for 
excretion as water-soluble compounds [181]. These transproters are also known as 
multidrug resistance proteins, because drug-resistant cancer cells use these proteins to 
protect themselves against chemotherapy drugs [182]. 




Although sometimes products of phase I detoxification are potentially more toxic than 
original substances, they do not impose any threat if phase II enzymes are functioning 
properly to rapidly neutralize products from phase I detoxification as they are formed. 
This delicate balance is upset by factors that can increase the activity of phase I more 
than phase II which leads to production of harmful metabolites faster than they can be 
detoxified, and increase the risk of cellular damage. Several factors including diet, 
smoking, age, disease or genetic composition of cells can cause this imbalance [183]. 
Several drugs, for example higher doses of acetaminophen [184] and anti-viral drugs 
have been found to have profound effects on this balance. Increased levels of toxins 
induce several types of damage to cells including nuclear and mitochondrial DNA 
damage, increased reactive metabolites, activation of apoptotic proteins, lipid 
peroxidation, mitochondrial dysfunction and inflammation. 
LIVER DAMAGE 
Several factors, as described above, can increase the risk of serious liver damage. If 
the liver is unable to clear toxins, drugs and metabolic by-products from blood, levels of 
these chemicals may increase in the blood, leading to impaired function of other organs. 
Sustained liver damage may result in fibrosis, steatosis, cirrhosis or liver cancer [185].  
Various complex and interactive mechanisms are involved in liver injury. Hepatotoxicity 
and drug-induced liver injury has been a major cause of acute liver failure [186, 187]. 
Biochemical mechanisms of liver injury mostly involve chemicals that are detoxified in 
the liver [187]. Some toxic metabolites may alter cell membrane [188], mitochondria 




Immune mechanisms mediated by cytokines, nitric oxide, and complement may also be 
involved on liver injury [166, 192]. Pathologic [193] and chemical [194] apoptosis is 
potentially another mechanism of acute liver injury. Knowledge of the involved 
mechanisms in liver injury at the cellular and molecular level may help to develop 
therapeutic strategies that might prevent liver failure. 
Liver injury can be determined by measuring the levels of certain liver enzymes in 
blood. Under normal circumstances, these enzymes are intracellular, which upon injury 
are released into blood [195]. Examples include aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and alkaline phosphatase [196]. Liver inflammation 
[197] and change [198, 199] in histological pattern of liver tissue are also useful to 
determine liver injury. 
Unlike most other differentiated cells, hepatocytes are capable of dividing in response to 
liver injury. Mitochondria in hepatocytes proliferate in response to cell division and 
energy needs [200]. However, if mitochondria are significantly damaged, mitochondrial 
division will not occur, and cell death and potentially liver failure will ensue. Aside from 
liver transplantation, there is currently no way to repair mitochondrial damage, or 
replace dysfunctional mitochondria [201]. Development of a method that could to deliver 
healthy and functional mitochondria to hepatocytes that can replace the dysfunctional 
mitochondria could help treat several mitochondrial hepatopathies caused due to direct 





Many different types of receptors are present on the surface membranes of cells. Some 
receptors recognize and bind to specific molecules or ligands present in extracellular 
environment, and internalize the receptor-ligand complex in membrane-limited vesicle, 
an endosome. Endosomes eventually fuse with lysosomes, which contain degradative 
enzymes resulting in breakdown of the internalized ligands. This whole process is called 
receptor-mediated endocytosis [202]. Hence, receptor-mediated endocytosis allows 
transport of macromolecules into cells through a complex series of intracellular 
transfers. Some surface receptors such as receptors for hormone, bile acid, and some 
types of glycoprotein receptors are specific for certain cell types [203]. 
 
ENDOSOMES 
After receptors on cell surface recognize and bind to specific molecules or ligands, cell 
membrane invaginates and the whole receptor-ligand complex is internalized by the cell 
in a membrane-enclosed vacuole called endosomes [204]. 
EARLY ENDOSOMES 
Early endosomes following entry of receptor-ligand complex are found near the 
periphery of cells. They are highly polymorphic, and can be up to 1 micron in size [205]. 
The size of endosomes changes with expression of different factors such as p97 
ATPases [206], Mon 1 a/b [207] and can lead to increase in size up to 1.5 microns. 
Early endosomes can be distinguished from other organelles with some specific 




[210].Early endosomes consist of a dynamic tubular-vesicular network which allows 
them to mature into late endosomes later [211]. Sorting of early endosomal content 
determines the subsequent fate of internalized ligands [212], directing them for recycling 
to the plasma membrane [213], degradation in lysosomes [214] or delivery to the trans-
Golgi network [215]. Through recruitment and assembly of the sorting machinery distinct 
microdomains are formed within early endosomes for sorting [216] followed by 
morphological changes in the early endosomal membranes.  
With help of newly formed tubular membranes recycling cargos and cargos for trans-
Golgi network are efficiently transported out of the early endosomes [217]. Remaining 
microdomains transform into late endosomes, and are directed towards degradation. 
Vesicles from the Golgi move towards endosomes with help of adaptors like GGAs and 
AP-1 clathrin-coated vesicles [218]. Retromer generates vesicles in early endosomes 
that move towards Golgi [219]. Further, mannose-6-phosphate receptors follow 
retrograde traffic pathway mediated by Rab9 and TIP47 and carry lysosomal hydrolases 
to early endosomes [220, 221]. After release of hydrolases in the acidic environment of 
endosomes, the receptor is retrieved to the Golgi by retromer and Rab9. This cross-talk 
between the Golgi and endosomes with the help of vesicles helps the early endosome 
to mature into late endosomes [222]. 
Molecules like receptors for LDL, EGF, and the iron transport protein transferrin, are 
concentrated in the tubules of early endosomes for recycling [213, 223, 224]. Other 
receptors like that for asialoglycoproteins, LDL and transferrin are released in 




by maturation of early endosomes to late endosomes. Several additional factors and 
pathways have been identified to play crucial role in early to late endosome transition 
[207]. 
LATE ENDOSOMES 
Late endosomes are found closer to nucleus than early endosomes; and are spherical. 
They lack tubules and have the appearance of multivesicular bodies (MVBs) [225]. They 
differ from early endosomes by their lower pH, different protein composition and 
markers. Because of delivery of vesicles containing lysosomal hydrolases from the 
Golgi, late endosomes become acidic. They have markers including RAB7 [226], RAB9 
[227], and mannose 6-phosphate receptors [228]. Time of delivery vary between cell 
types and between cells in culture and in living tissue from minutes to several hours 
(half-life 6 hours) [229]. Lysosomal integral membrane glycoproteins are delivered from 
trans-Golgi network with the help of adaptor AP-3 [229]. Late endosomes can fuse with 
other late endosomes [230] resulting into morphological remodeling or can fuse with 
lysosomes [229] leading to degradation of endosomal contents. Certain proteins serve 
to reform late endosomes and hence are recycled out of late endosomes to the Golgi to 
avoid degradation [231]. 
 
LYSOSOMAL DEGRADATION 
Lysosomal proteolysis is one of major protein degradation pathways in cells. 
Lysosomes contain an array of digestive enzymes that play major role in cell 




and gradual turnover of cytoplasmic proteins and organelles [232]. Lysosomes prevent 
uncontrolled destruction of cellular contents by containment of digestive enzymes and 
proteases [233]. Therefore, lysosomal degradation requires fusion of vesicles 
(autophagosomes or endosomes) to the lysosomes [234].  
Autophagosomes are membrane enclosed small regions of cytoplasm or cytoplasmic 
organelles derived from the endoplasmic reticulum [235]. Fusion and digestion of 
autophagosomes by lysosomal enzymes allow the cells to maintain homeostasis in 
cellular environment [236].  
Late endosomes formed after maturation of early endosomes contain processed 
internalized extracellular proteins destined to digestion. Lysosomes are denser than late 
endosomes and the hybrids have an intermediate density [237]. Transport from late 
endosomes to lysosomes is also unidirectional, as late endosome are consumed in the 
process of fusion to a lysosome [238]. Hence, endosomal content end up degraded in 
lysosomes unless they escape or are retrieved in some way.  
Lysosomal degradation helps the cells to degrade and recycle the products of the 
internalized substances in endosomes or autophagosome. Hence this process is 
required to maintain homeostasis and growth of cells and tissues [239, 240].    
 
ASIALOGLYCOPROTEIN RECEPTORS (AsGR) PATHWAY 
The asialoglycoprotein receptor (AsGR)-mediated endocytosis is one of the most 




differentiated hepatocytes, providing the cells a membrane bound active site for cell to 
cell interactions and mediating other activities like uptake of selective agents and 
viruses. Several factors govern the AsGR activity and distribution in cells, such as sub 
unit interactions [241] or post-translational modifications [242]. AsGR is composed of 
two protein sub-units and both are required for its functional binding activity [243] and 
distribution [244]. Post-translational glycosylation of AsGR also has a major impact on 
its physiological status [242]. AsGR requires calcium (Ca2+) for ligand binding [241] and 
has high affinity for the galactose-terminating oligosaccharides of desialylated 
glycoproteins, facilitating their uptake and degradation by parenchymal hepatocytes 
[245]. Confluent cells show increased levels of AsGR expression compared to cells that 
are actively dividing.   
Glycoproteins are proteins which have glycan residues, carbohydrate chains, covalently 
bound to polypeptide side chains of proteins during post-translational modification called 
glycosylation. Glycoproteins play various essential roles in human body. The glycan 
residues of human glycoproteins frequently have exposed sialic acid groups at the ends 
of the chains [246] which helps keeping the protein functional. These sialic acid 
residues are lost over time with a number of enzymatic and metabolic activities, 
exposing the penultimate sugar, galactose.  
AsGRs present on the surfaces of hepatocytes recognize and bind to exposed 
galactose residues of asialo-glycoproteins (AsGs) [247]. Binding of AsGs to AsGRs 
triggers invagination of the cell membrane, and eventually internalizing the AsGR-AsG 
complexes within endosomes (Figure 1.2) Endosomes are short-lived, and appear to 




decreases [249], uncoupling of receptor-ligand complex starts [248]. Subsequent to 
dissociation, AsGR is recycled back to cell surface for re-use [250]. AsGs have been 
used as a targetable carriers to deliver genetic material or macromolecular drugs 
specifically to hepatocytes using soluble complexes of DNA/drugs and AsGs both in 
vitro [251, 252] and in vivo [253]. AsGR-mediated pathway is degradative since after 
internalization endosomal contents are subjected to degradation by lysosomal fusion 
(Figure 1.2) into constituent smaller products. This process can be arrested if lysosomal 
digestion is inhibited, which can be accomplished specifically by increasing the pH of 
endosomes or increasing the release of endosomal contents into cytoplasm before 
lysosomal fusion.   
 
ENDOSOMAL ESCAPE 
Development of methods for efficient and specific delivery systems is an important issue 
in success of delivery and application of drugs and gene therapy [254]. Since the major 
uptake mechanism of cells is endocytic pathway, most drugs and agents are entrapped 
in endosomes, and subsequently are degraded by lysosomal digestion which limits the 
effects of delivered agents [255]. Several mechanisms to facilitate the endosomal 
escape and increase cytoplasmic delivery are under investigation. Bacteria and viruses 
use several mechanisms such as formation of pores in the endosomal membrane, 
changes in pH of endosomes/lysosomes and fusion membrane of endosomes to enable 
the endosomal escape [256]. Chemical agents, synthetic polymers/peptides and 




optimal agent for endosomal escape is required which should have high efficiency and 
no toxicity. Understanding the mechanism of escape of endosomal contents with the 
help of different agents is important to develop the therapeutic agents. 
Following are a few known mechanisms of endosomal escape: 
PORE FORMATION IN THE ENDOSOMAL MEMBRANE 
 Some agents or peptides can bind and cause decrease in tension of the membranes 
resulting in pore formation in endosomal membranes [258]. Some peptides can 
polymerize to make barrel-stave pore or toroidal pore giving rise to holes in membranes 
[259].  
pH-BUFFERING EFFECT 
Some agents can alter the protonation in endosomes which induces influx of water and 
ions into endosome that subsequently causes rupture of endosomes and release of 
endosomal contents in cytoplasm [260]. 
ENDOSOMAL MEMBRANE FUSION 
Some fusogenic peptides, commonly found in viruses, undergo conformational changes 
when triggered by change in pH in endosomes allowing the protein to induce fusion in 
membrane [261]. This induces fusion of membrane of biologic agent to endosomal 
membrane and hence releasing the internal contents of biological agent in the 
cytoplasm  
PHOTOCHEMICAL INTERNALIZATION 
Several photosensitizers localize in the membrane of the endosomes and lysosomes 
[262] and induce reactive oxygen formation upon exposure to light, which destroy 




Several potential agents to enhance endosomal escape are under investigation to 
improve the drug and gene therapy effects. Following are few examples of types of 
escape agents being studied: 
MEMBRANE-ACTIVE PROTEINS AND PEPTIDES 
Usually derived from biological agents like virus, bacteria or plants and made more 
desirable by recombinant technologies, protein and peptide based agents are most 
promising group of endosomolytic agents. 
Virus derived agents: Examples, haemagglutinin (HA) protein of the influenza virus has 
fusogenic properties [264], influenza-derived fusogenic peptide diINF-7 [265], fusogenic 
penton base protein of adenovirus [266], pore forming gp41 transmembrane protein of 
HIV [267], Tat protein of HIV causes membrane destabilization [268], membrane-
disrupting L2 peptide of Papillomavirus [269], fusogenic envelope protein (E) of the 
West Nile virus [270]. 
Bacteria derived agents: Examples, pore-forming listeriolysin O (LLO) from Listeria 
monocytogenes [271], pore-forming toxins Pneumococcal pneumolysin (PLO) and 
Streptococcal streptolysin O (SLO) [272], fusogenic peptide Diphtheria toxin (DT) 
secreted by Corynebacterium diphtheria [273], fusogenic exotoxin A (ETA) from 
Pseudomonas aeruginosa, [274],  
Plant derived agents: Examples, ribosome-inactivating protein, Ricin from Ricinus 





Human / animal derived agents: Examples, human calcitonin derived peptide, hCT(9-
32) causes lipid raft-mediated endocytosis [277], fibroblast growth factors (FGFs) 
(mechanism not known) [278], Melittin, bee venom, induces membrane destabilization 
[279]. 
Synthetic peptides: Examples, Arginine-rich cell-penetrating peptides called (R-Ahx-
R)(4) AhxB, binds to proteoglycans on membranes [280], fusogenic synthetic analogue 
of glycoprotein H (gpH) [281], small peptide sequences derived from haemagglutinin 
subunit HA-2 [282] and GALA [283] of influenza virus, penetratin (pAntp), a domain of 
antennapedia protein [284], R6-penetratin [285], synthetic analog of penetratin EB1 
destabilizes the endosomal membrane [286], bovine prion protein (bPrPp) [287], 
Histidine-rich peptides [288], sweet arrow peptide (SAP) [289]. 
MEMBRANE-ACTIVE CHEMICAL AGENTS  
Several chemical agents with endosome disruptive properties are also being developed. 
Example, polyethylenimine (PEI) [290] and imidazole-containing polymers [291] cause 
pH changes, agents such as ammonium chloride, chloroquine, and methylamine 
penetrate the cell membranes and alter pH [292] 
For effective delivery of drugs and agents, to reduce the risk of degradation and 
increase chances of safe release of therapeutic gene/protein/drug, it would be ideal to 





We hypothesized that: 1) Isolated mitochondria can be coated with positively charged 
AsGs in a non-damaging electrostatic interaction. 2) These AsG–mitochondria 
complexes could be targeted to hepatocytes, which would recognize and bind to AsGR 
on cell surface. Complexes could be internalized by hepatocytes through AsGR-
mediated endocytosis. 3) An endosomolytic agent could be used to facilitate the escape 
of internalized mitochondria from lysosomal digestion. 4) Healthy mitochondria delivered 
to hepatocytes with defective or damaged mitochondria could substitute for the 
damaged organelles, and proliferate until the energy requirements of the cell were met 





The aim of the study was to determine whether healthy and functional mitochondria 
could be targeted to hepatocytes, substitute for the damaged organelles, and proliferate 
to meet the energy requirements and correct the mitochondrial dysfunctional disorders 






CELLS AND CELL CULTURE  
Suitable cell culture models are required to study uptake of AsG-coated mitochondria by 
hepatocytes and for further assays to evaluate stability and function of the mitochondria 
delivered to the hepatocytes specifically. Cells showing AsGR mediated activity to 
evaluate internalization and for source of mitochondria to make complexes with AsGs 
were required.   
 
MODEL SYSTEM FOR EVALUATING UPTAKE BY HUMAN HEPATOCYTES 
HUH 7 CELLS  
Human hepatoblastoma cells, Huh 7 cells, AsGR (+) are well-differentiated transformed 
liver cells. These cells express AsGR on cell surface and have been shown to actively 
internalize AsGs through AsGR mediated endocytosis [293]. Unlike other common 
AsGR expressing hepatoma cell lines, Huh 7 cells grow in monolayers. Huh 7 cells 
were used to evaluate binding and internalization of AsGs coated mitochondria and 
stability and function of delivered mitochondria.    
SK HEP1 CELLS 
Human hepatoma cells, SK Hep1 cells [AsGR (-)] is a poorly-differentiated, transformed 
liver cell line. These cells do not exhibit many hepatic-specific features [294]. In 
particular, SK Hep1 cells express little AsGR on cell surface. These cells were used as 
negative controls to determine if internalization of AsGs coated mitochondria by Huh 7 




SOURCE OF MITOCHONDRIA FOR UPTAKE ASSAYS 
HTC CELLS 
HTC is a well-differentiated rat hepatoma cell line [295]. HTC cells were used as source 
cells to obtained mitochondria for complex formation with AsGs and internalization by 
human hepatocytes expressing AsGR on cell surface. These cells have mitochondrial 
DNA sequences different than human mitochondrial DNA sequences that can be 
distinguished using PCR amplification with specific primers for respective cell 
mitochondrial DNA sequences. Despite of 70% homology, specific sets of primers have 
been used to differentiate between human and rat mitochondrial DNA [47].This helps in 
differentiating between cellular endogenous mitochondria and internalized mitochondria 
from extracellular environment in human hepatocytes after uptake of AsG-coated 
mitochondria. 
 
SOURCE OF GFP-LABELED MITOCHONDRIA 
HTC MITO-GFP CELLS  
HTC mito-GFP cell line was genetically constructed by transfecting HTC cells with 
pAcGFP1-Mito plasmids (Clontech Laboratories) expressing green fluorescent protein 
(GFP) fused to a mitochondria targeting sequence (subunit VIII of human cytochrome c 
oxidase). When expressed in cells, subunit VIII of cytochrome c oxidase carry fused 
GFP to inner membranes of mitochondria and labeling the mitochondria with GFP. GFP 
labeled cells were selectively sorted using fluorescence-activated cell sorter to construct 
a stable HTC mito-GFP cell line and kept under selective pressure. These cells were 








HUH 7-MITO (-) AND SK HEP1-MITO (-) CELLS 
Huh 7 and SK Hep1 cells have high numbers of mitochondria to meet energy 
requirement of cells. To eliminate the background human mitochondria so that chances 
of propagation of newly delivered mitochondria increase, damage to endogenous 
mitochondria of cells was required. Delivery of external mitochondria to cells with 
damaged mitochondria would also help to determine stability and function of delivered 
mitochondria. 
Mitochondria in cells can be damaged by treatment with various types of mitochondrial 
toxins. Continuous damage to mitochondria in cells can result in cells with permanently 
damaged mitochondria and cell death unless cells are supported artificially by providing 
required supplement materials externally. 
Huh 7 and SK Hep1 cells were treated with 2’-3’-dideoxycytidine (ddC), zalcitabine. ddC 
is a pyrimidine analog derived from deoxycytidine, by replacing the hydroxyl group in 
position 3' with a hydrogen terminating the chain elongation during DNA replication 
[296]. Although both nuclear and mitochondrial DNA replications are susceptible to ddC, 
mitochondrial DNA replication is more affected in presence of ddC because of 
significantly smaller size of mitochondrial DNA compared to nuclear DNA [297]. 




eventually forming mitochondrial DNA free cells [298]. Mitochondrial structures (inner 
and outer membrane of mitochondria) are still found in cells since structural proteins 
composing those are expressed by mitochondrial genes in nucleus. However, due to 
complete loss of mitochondrial DNA, expression of mitochondrial genes from 
mitochondrial DNA is absent, which causes complete loss of mitochondrial respiration 
and function.   
Huh 7-mito (-) and SK Hep1-mito (-) cells were constructed by treatment with ddC for 2-
3 weeks. Complete loss of mitochondrial DNA was determined with real-time PCRs. 
Cells were supported with L-glutamine, sodium pyruvate and uridine [299] externally to 
avoid cell death. These mitochondria free cells allowed elimination of background 







Figure 1.1. Mitochondrial Genotypic Mutations Associated with Human 
Mitochondrial Disorders. 








Figure 1.2. A schematic representation of AsGR-mediated endocytosis of AsGs 
by hepatocytes. 
AsGR on cell membrane bind to AsG, followed by internalization of AsGR-AsG 
complexes in endosomes. These endosomes fuse with lysosomes resulting in 





Figure 1.3. A representation of targeted LLO-mediated endosomal rupture 
After internalization of LLO conjugates in endosomes, LLO becomes activated in the 
low pH and reducing environment of endosomes which results in pore formation and 
rupture of endosomal membranes. This allows the escape of endosomal contents in 





CHAPTER 2: FORMATION OF STABLE COMPLEXES OF 
MITOCHONDRIA WITH AsG. 
In order to evaluate binding and internalization of asialo-glycoprotein (AsGs)-
mitochondria complexes with hepatocytes, coating of mitochondria with AsGs is 
required so that cells could recognize the AsGs and take the whole complex in.  
However, mitochondrial membranes are delicate and susceptible to damage. In 
particular, covalent bonding could alter or destroy important membrane structures. 
Since, the surface of mitochondria is known to be negatively charged (See Chapter 1), 
preparation of an AsG that was highly positively charged, could result in a non-covalent 
electrostatic complex formation by mixing of the carrier with mitochondria.  
Poly-L-lysine refers to a synthetic polymer composed of a positively charged amino 
acid, lysine. Coupling of poly-lysine chains to other proteins provides positive charge to 
those proteins. Poly-lysines can be coupled with other proteins using carbodiimide 
cross-linkers. Carbodiimides (1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide) are 
water soluble hydrochloride cross-linkers used as carboxyl activating agents to couple 
primary amines to yield amide bonds [300]. Hence, carbodiimides help binding two 
protein molecules covalently. Depending on number of lysine residues, poly-lysine 
chains can vary in length, which also results in varying amount of additional positive 
charge added to the coupled protein molecules. Larger size of poly-lysine chains can 
provide higher amount of positive charges to the desired protein, which can result in 
formation of aggregates when used to make complexes with negatively charged 




used to stably bind to AsGs using carbodiimides cross-linkers to avoid aggregation of 
AsGs-mitochondria complexes when added to isolated mitochondria. 
 
ASIALO-OROSOMUCOID PROTEIN CARRIER 
Orosomucoid (OR) is an abundant human plasma glycoprotein (normal plasma 
concentration between 0.6-1.2 mg/mL [301]). OR was de-sialated to remove terminal 
sialic acid groups enzymatically and form asialoorosomucoid (AsOR) with exposed 
glycan residues to make complexes with isolated mitochondria. AsOR is an extensively 
studied AsG that is recognized and internalized by hepatocytes via AsGR mediated 
endocytosis [302] and has been used for targeted delivery of other drugs/ proteins and 
genes specifically to hepatocytes [252, 303].  
To follow and measure uptake of the carrier by hepatocytes, AsOR was labeled with 
fluorescence dylight 650 dye to construct fluorescence labeled AsOR (Fl-AsOR). Fl-
AsOR is negatively charged. To convert Fl-AsOR to a positively charged molecule, poly-
lysine chains were covalently coupled to the protein using carbodiimides cross-linkers to 
create positively charged poly-lysine tagged Fl-AsOR (Fl-AsOR-PL). Changes in 
charges on the protein were determined with gel electrophoresis. Proteins were loaded 
in the middle of the gel such that positively charged proteins could run towards negative 
terminal and negatively charged proteins could run towards positive terminal. Average 
number of fluorescent tags and poly-lysine chains bound per AsOR molecule were 
calculated. Addition of fluorescent tags and poly-lysine chains could have altered the 




assays were performed to determine if after addition of fluorescent tags and poly-lysine 
chains, Fl-AsOR-PL is still being recognized by hepatocytes. Fl-AsOR-PL was 
anticipated to bind to isolated mitochondria by electrostatic interactions.  
 
FORMATION OF STABLE COMPLEXES OF Fl-AsOR-PL AND 
MITOCHONDRIA 
Fl-AsOR-PL is a positively charged protein, and isolated mitochondria have a negatively 
charged outer membrane. Isolated mitochondria and Fl-AsOR-PL were mixed to form 
Fl-AsOR-PL–mitochondria complexes by an electrostatic interaction (Figure 2.1). To 
deliver the mitochondria to hepatocytes via AsGR mediated endocytosis, complexes of 
Fl-AsOR-PL–mitochondria should be stable such that Fl-AsOR-PL remains bound to the 
mitochondria through whole process. Stability of the complexes was determined by 
centrifuging and re-suspending the mitochondria in fresh medium. If the complex is 
stable, Fl-AsOR-PL would stay bound to mitochondria upon repeated centrifugation, 






CELLS AND CELL CULTURE 
Huh 7, SK Hep1 and HTC cells were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) (Gibco) supplemented with antibiotic/antimycotic solution (Invitrogen), 10% 
fetal bovine serum (FBS) (Invitrogen). 
MITOCHONDRIA PREPARATION 
Isolation of mitochondria is a delicate and time-consuming procedure. Composition of 
isolation buffers and storage buffers directly affect stability and function of isolated 
mitochondria [304]. It has been shown that the use of monosaccharides such as 
mannitol helps in isolation of better coupled isolated mitochondria [305]. Cells were 
lysed manually because detergents can cause denaturation of mitochondrial membrane 
proteins and result in swelling of mitochondria [306]. Since addition of tris chloride 
based buffers have shown to cause aggregation of isolated mitochondria [307], 
phosphate based buffers were used to isolate and store isolated mitochondria [308]. 
Recommended conditions and ionic concentrations were used to isolate mitochondria 
from hepatocytes and store isolated the mitochondria [309]. 
Mitochondria were isolated from HTC and Huh 7 cells using a mitochondria isolation kit 
for mammalian cells (Thermo Scientific, Rockford, IL, USA) according to manufacturer’s 
instructions. In brief, cells were pelleted by centrifuging approximately 2 x 107 cells at 
800 x g for 5 min and re-suspended in 800 µl of mitochondria isolation reagent A from 




mitochondria isolation kit was added and cells were vortexed intermittently for 5 min on 
ice. Isolation reagent C from mitochondria isolation kit, 800 µl, was added and mixed 
gently. Cell lysate was centrifuged at 1000 x g for 15 min at 4°C. Supernatant was 
collected and spun at 4000 x g for 20 min at 4°C. Mitochondria pellet was collected and 
washed with reagent C from mitochondria isolation kit. After purification, mitochondria 
were kept in isolation reagent C from the mitochondria isolation kit on ice until further 
use. 
CARRIER PREPARATION 
Orosomucoid (OR) was isolated from human serum (American Red Cross) by the 
procedure of Whitehead and Sammons [310].  OR was de-sialated by neuraminidase 
(Sigma) [311] to make asialo-orosomucoid (AsOR).  AsOR was labeled with dylight 650 
using an NHS ester reaction (Thermo Fisher Scientific Inc., Rockford, IL USA) 
according to manufacturer’s instructions. AsOR and fluorescence labeled AsOR (Fl-
AsOR) were separately reacted with a carbodiimide cross-linker (Sigma) followed by 
addition of poly-L-lysine (PL) in 1 ml of 0.1 M MES (pH 6) for 24 h at 25°C. Excess PL 
was removed from AsOR-PL and Fl-AsOR-PL separately using an exclusion column 
(10,000 MWCO, Millipore). Fl-AsOR and Fl-AsOR-PL, 1 µg each in 100 µl in phosphate 
buffered saline (PBS), were used to check fluorescence intensity using an 
XFLUOR4SAFIREII Version: V 4.62n spectrophotometer. 
To evaluate the charge of proteins, samples were mixed with 60% glycerol and loaded 
in wells in the center of an 0.8% agarose gel, run at 100V for 1 h with Tris-acetate-




with 0.1% amido black (Bio-Rad) in 40% methanol and 10% acetic acid for 30 min, and 
de-stained with 40% methanol and 10% acetic acid for 10-13 h at 25°C on a rotary 
shaker. 
MASS SPECTROMETRY 
AsOR, Fl-AsOR and Fl-AsOR-PL were diluted to 1, 0.1, 0.025 and 0.001 mg/ml. 
Lysozyme (MW 14.3 kDa) (Sigma) and bovine serum albumin (BSA) (MW 66.5 kDa) 
(Sigma) were used as controls. Matrix suitable for large analytes, 3, 5-dimethoxy-4-
hydroxycinnamic acid (sinapinic acid), (Sequazym Peptide Mass Standards Kit, Applied 
Biosystems) was mixed with various concentrations of proteins with or without controls 
according to manufacturer’s instructions, and submitted for mass spectrophotometry 
(Voyager-MALDI). 
COMPLEX FORMATION AND STABILITY 
Rat (HTC) cell mitochondria, 800 µl (1.6 µg/µl total mitochondria protein) in 
mitochondria isolation reagent C were incubated with 100 µg of Fl-AsOR-PL or Fl-AsOR 
protein (in 52 µl PBS) on ice for 45 min. Samples were repeatedly spun at 4000 rpm for 
8-10 min at 4°C, and re-suspended in mitochondria isolation reagent C.  After each 
spin, the mitochondria pellets and supernatants were collected, and fluorescence 
measured at 685 nm. Experiments were conducted in triplicate, and repeated 3 times. 






PARTICLE SIZE ANALYSIS 
Fl-AsOR-PL, 100 µg, was added to isolated mitochondria, 400 µl  (3 µg/µl total 
mitochondrial protein) and incubated on ice for 45 min. Fl-AsOR-PL–mitochondria 
complexes were centrifuged at 4000 rpm for 10 min at 0°C, washed and re-suspended 
twice in mitochondria reagent C, 800 µl. Mitochondria or Fl-AsOR-PL–mitochondria 
complexes, 8 µl, were analyzed on a 90Plus Particle Size Analyzer (Brookhaven 
Instruments Corporation, Holtsville, NY, USA). Each sample was run eight times, and 
assays repeated with 4 independent replicates. Results are expressed as mean 
effective diameter ± standard error (nm). 
UPTAKE ASSAY BY FLUORESCENCE MICROSCOPY  
Cells were plated at 50% confluence on sterile cover slips 2-3 days before assay. When 
95% confluent, cells were washed with PBS (Mg2+-and Ca2+-free) and maintained in 
phosphate-free DMEM with high glucose (Life Technologies, #11971) for 16 h.  Cells 
were incubated with Fl-AsOR-PL at 37°C for 1 h. After uptake, cells were washed 3 
times with 10 mM EDTA in ice cold PBS (Mg2+-and Ca2+-free) and fixed with 4% 
paraformaldehyde for 30 min and nuclei were stained with DAPI (Invitrogen) for 20 min. 
Cells were mounted and imaged under a fluorescence microscope, and presented as 






RESULTS AND DISCUSSION 
Fluorescence spectrophotometric data showed high intensity of fluorescence in both Fl-
AsOR and Fl-AsOR-PL (Figure 2.2). The fluorescence value of 1 µg Fl-AsOR was 
28,000 units, and of Fl-AsOR-PL it was 27,600 units in 100 µl of PBS. This suggested 
that protein was labeled with a fluorescent tag, which could help to measure 
fluorescence levels in cells after uptake.  
To determine if charge of Fl-AsOR-PL is changed from negative to positive upon 
addition of poly-lysine chains, an agarose gel was run. Gel electrophoresis showed that 
AsOR and Fl-AsOR were negatively charged, and migrated towards the positive 
terminal. Fl-AsOR-PL migrated towards negative terminal indicating that the addition of 
poly-lysine chains converted the negatively charged molecule into a positively charged 
one (Figure 2.3).  
Average masses determined by mass spectrometric analysis were AsOR, 32.8 kDa; Fl-
AsOR, 33.4 kDa; and Fl-AsOR-PL, 35.2 kDa. From these data and the known 
approximate mass of dylight tag (0.25 kDa) and PL (1 kDa), it was calculated that an 
average of two fluorescent tags and two PL chains were bound per Fl-AsOR-PL 
molecule (Figure 2.4).  
Chemical linkage of fluorescent tags and poly-lysine chains to AsOR might have altered 
AsOR recognition by AsGRs. To evaluate binding of Fl-AsOR-PL to AsGRs, Huh7 
[AsGR (+)] cells and SK Hep1 [AsGR (-)] cells were incubated with Fl-AsOR-PL. 
Fluorescence microscopy showed that approximately 78% of cell population had 




nuclei (Figure 2.5C) suggesting that those structures were intracellular, and the size 
was consistent with that of endosomal vesicles. In contrast, SK Hep1 cells [AsGR (-)] 
lacked any similar red structures (Figure 2.5B and D). This suggested that Fl-AsOR-PL 
was internalized by Huh 7 cells by AsGR-mediated endocytosis. Internalization was not 
found uniform in all the cells, but was in groups of cells where cells were lying in close 
proximity. This could be because of the higher expression of AsGR in confluent cells 
compared to dividing cells (See Chapter 1). Plane of focus of microscopy is another 
factor that affects the observation of Fl-AsOR-PL in all cells in a field. Difference in 
localization of early and late endosome (See Chapter 1) makes it difficult to observe 
internalization in all cells in one plane since cells might take different amount of times in 
endosomal maturation and hence different plane of localization of internalized protein. 
If there is stable binding of Fl-AsOR-PL with mitochondria, particle size of mitochondria 
is anticipated to increase after coating those with Fl-AsOR-PL. Particle size analysis of 
mitochondria alone showed a mean diameter of 700 ± 57.8 nm, while purified Fl-AsOR-
PL–mitochondria complexes had a mean diameter 1000 ± 62 nm, Figure 2.6, 
suggesting that the complexation increased the mean diameter of mitochondria by 
approximately 43%. 
Complexes of positively charged Fl-AsOR-PL and isolated mitochondria were 
anticipated to be stable with charge-charge interactions. The stability of the Fl-AsOR-
PL–mitochondria complexes was determined by repeatedly centrifuging and re-
suspending the complexes in fresh medium. As shown in Figure 2.7A, fluorescence of 
the Fl-AsOR-PL associated with the pelleted mitochondria decreased by about 15% 




through three spins. Conversely, fluorescence in the supernatants of Fl-AsOR-PL mixed 
with mitochondria decreased to 24% from 32,000 to 7,900 units in supernatant after 1st 
spin and remained low in subsequent spins, Figure 2.7B. The mitochondrial pellet-
associated fluorescence after mixing of mitochondria with Fl-AsOR that lacked PL, was 
4,000 units (< 10% of fluorescence of the Fl-AsOR added) after the first spin, and no 
longer detected with the pelleted mitochondria after the 2nd and 3rd spins, Figure 2.7A. 
These data suggested that Fl-AsOR-PL binding to mitochondria required the presence 
of PL, and the binding was stable under the conditions of re-suspension and 
centrifugation. 
These data showed that we were able to make stable complexes of Fl-AsOR-PL–
mitochondria. These stable Fl-AsOR-PL–mitochondria complexes were used further to 







Figure 2.1. A representation of electrostatic binding of an Fl-AsOR-PL conjugate 
to mitochondria. 
Positively charged Fl-AsOR-PL binds to negatively charged isolated mitochondria to 






Figure 2.2. Fluorescence of proteins tagged with Dylight 650 dye. 





































Figure 2.3. Gel electrophoresis showing the direction of migration of Fl-AsOR and Fl-
AsOR-PL. 
Proteins were loaded near the middle of a 0.8% agarose gel to determine the charge by 
direction of migration. Negatively charged proteins (AsOR and Fl-AsOR) ran towards 
positive terminal and positively charged protein (Fl-AsOR-PL), PL, and a positive 





Figure 2.4. Mass spectrometric data.  
Purified AsOR, Fl-AsOR and Fl-AsOR-PL with or without internal controls (lysozyme 
and bovine serum albumin (BSA)) were mixed with a sinapinic acid matrix, and loaded 
on a mass spectrometric plate to determine masses. Spectral peaks were calibrated as 








Figure 2.5. Fl-AsOR-PL uptake analysis by fluorescence microscopy. 
Uptake of Fl-AsOR-PL by Huh 7 cells (A and C) and SK Hep1 cells (B and D) was 
determined with fluorescence microscopy after incubation for 1 h at 37°C. A-B, Fl-







Figure 2.6. Particle size analysis by light scattering. 
Fl-AsOR-PL was added to isolated mitochondria to make complexes. The size of 
isolated mitochondria, and Fl-AsOR-PL–mitochondria complexes in saline was 







Figure 2.7. Stability of Fl-AsOR-PL–mitochondria complexes. 
Freshly isolated rat mitochondria were incubated with Fl-AsOR-PL or Fl-AsOR and 
repeatedly centrifuged and re-suspended in fresh medium. A. Fl-AsOR-PL or Fl-AsOR 




CHAPTER 3: ASSESSMENT OF BINDING AND UPTAKE OF 
AsG–MITOCHONDRIAL COMPLEXES BY MODEL CELLS 
To determine whether hepatocytes could recognize and internalize stable complexes of 
Fl-AsOR-PL–mitochondria through AsGR-mediated endocytosis, Huh 7 cells and SK 
Hep1 cells were incubated separately with Fl-AsOR-PL–mitochondria complex. We 
hypothesized that cells would be able to recognize the Fl-AsOR-PL around the 
mitochondria, which would allow the cells to internalize the whole Fl-AsOR-PL–
mitochondria complexes.  
Compared to dividing cells, AsGR expression is higher in confluent cells. So cells were 
grown to more than 95% confluence before uptake assays were performed. Human 
hepatocytes are maintained in cell culture media containing 10% serum. This serum 
competes with internalization of desired complexes. In order to avoid this competition, 
cells were washed and kept in serum free media for 12-18 h before uptake assays to 
allow recycling of receptors back to cell surface.  
Cells were incubated with Fl-AsOR protein alone as a positive control for AsGR-
mediated endocytosis. In order to determine whether internalization was AsGR 
mediated and not random, cells were also incubated with mitochondria alone. Detection 
of internalized mitochondria in cells incubated with mitochondria alone would suggest 
that internalization was not specific. Cells were also pre-incubated with an excess AsOR 
prior exposure to Fl-AsOR-PL–mitochondria complex at 37°C to compete with AsGR 




Endocytosis is a continuous process. Therefore, continuous internalization should show 
increasing levels of endocytosed substances in cells with time before degradation 
begins. Uptake assays were performed for different time periods to determine if 
increase in internalized complexes is a function of time. 
After uptake assays, internalization of the protein carrier, Fl-AsOR-PL was determined 
by measuring fluorescence intensity in cells. HTC cells were used as source of 
mitochondria as mitochondrial DNA sequences in HTC cells are distinguishable from 
human hepatocyte mitochondrial DNA sequences. This allows differentiating between 
endogenous mitochondria and internalized mitochondria in cells.  Uptake of HTC 







Cells were plated at 50% confluence on tissue culture plates 2-3 days before assay. 
When 95% confluent, cells were washed with PBS (Mg2+- and Ca2+-free) and 
maintained in phosphate-free DMEM with high glucose (Life Technologies, #11971) for 
16 h.  Mitochondria were isolated from HTC cells, and complexed with Fl-AsOR-PL. 
Uptake assays were conducted at 37°C in DMEM, 2.8 mM Ca2+ [312] to which was 
added either 20 µg/ml mitochondria alone, 4 µg/ml Fl-AsOR alone, 25 µl/ml Fl-AsOR-
PL–mitochondria complex, or 25 µl/ml Fl-AsOR-PL–mitochondria complex + 200 µg/ml 
AsOR (100-fold molar excess added 4 min prior to uptake). Assays were repeated with 
3 independent replicates. 
After uptake, cells were washed 3 times with 10 mM EDTA in ice cold PBS (Mg2+-and 
Ca2+-free) followed by washes with ice cold PBS at each time point or at 2 h for 
extended experiments. Cells were either trypsinized with 0.05% trypsin-EDTA (Gibco, 
Life Technologies) and collected by centrifugation at 800 rpm for 4 min at 4°C or lysed 
with 200 µl lysis buffer (Buffer A, mitochondria isolation kit, Thermo Scientific). 
Fluorescence intensity of Fl-AsOR-PL in lysed cells was measured using 
XFLUOR4SAFIREII Version: V 4.62n spectrophotometer. HTC mitochondrial DNA 
levels in trypsinized cells or cell lysates were quantitated by qPCR. Experiments were 
conducted in triplicate, and repeated at least 3 times. 




To measure uptake of mitochondria, primers (Table 3.1) were designed using Primer3 
[313] and Primer-BLAST [314] to specifically amplify Huh 7 mitochondrial DNA or rat 
liver (HTC) mitochondrial DNA. Primer specificity was determined by PCR using DNA 
extracted from Huh 7 and HTC cells with QIAamp DNA mini kit (Qiagen) according to 
the manufacturer’s instructions.  
For uptake studies, whole cell DNA was isolated using QIAamp DNA mini kit (Qiagen) 
and mitochondrial DNA levels were quantified by qPCR with Power SYBR Green PCR 
Master Mix (Applied Biosystems) according to manufacturer’s instructions. Human 
lactate dehydrogenase A (LDHA) DNA levels were quantified in each sample using 
primers specific for the human LDHA isomer, and the results used to normalize 
mitochondrial DNA levels (Table 3.1). The qPCR conditions were: one cycle of 2 min at 
50°C, and 10 min at 95°C; 40 cycles of 15 sec at 95°C, and 1 min at 60°C followed by 
one cycle of 10 min at 55°C. Melt curves were obtained following each qPCR to search 
for primer dimers, and analyze the specificity of the reaction with following conditions: 
15 sec at 95°C, 15 sec at 60°C and 15 sec at 95°C. Assays were repeated with 3 
independent replicates. Raw data from qPCR were analyzed using comparative real-
time PCR kinetics formula [315] and the results expressed as means ± standard error of 
fold changes in mitochondrial DNA levels (i.e. mitochondrial DNA number per cell) 
compared to untreated controls. Non-specific uptake was determined from amplification 
levels in untreated cells. The number of specific mitochondrial DNA copies in treated 
cells was determined by difference between total amplification in treated cells and non-
specific amplification in untreated cells. The number of mitochondrial DNA copies per 




cells by the number of nuclear LDHA DNA copies per cell [316]. The average number of 
mitochondria per cell was calculated by dividing number of mitochondrial DNA copies 





RESULTS AND DISCUSSION 
After washing of the cells with EDTA-PBS to remove surface bound protein, the level of 
fluorescence in Huh 7 cells, AsGR (+) incubated with Fl-AsOR alone was approximately 
15,000 units at 15 min, and increased to more than 20,000 units at 60 min, Figure 3.2A. 
Similarly, fluorescence in Huh 7 cells incubated with Fl-AsOR-PL–mitochondria complex 
was 20,000 units at 15 min, and increased to more than 35,000 units at 60 min. As 
expected, fluorescence levels after incubation of mitochondria alone (lacking labeled 
AsG) had no fluorescence. Furthermore, addition of a large molar excess of AsOR prior 
to Fl-AsOR-PL–mitochondria complex resulted in fluorescence levels less than 2,500 
units at both 15 min and 60 min in Huh 7 cells, Figure 3.2A. These results indicated that 
association of protein carrier with Huh 7 cells was time-dependent, and inhibited by 
competition with excess of free AsOR supporting the conclusion that association of 
protein carrier with Huh 7 cells was mediated by the AsGR. Fluorescence in SK Hep1, 
AsGR (-) cells was barely detectable under all conditions, Figure 3.2B which further 
suggest that time-dependent increase in fluorescence levels in Huh 7 cells was not 
random. 
However, because the fluorescent tag was only on the Fl-AsOR-PL carrier, it is possible 
that the carrier alone, without mitochondria, was internalized. To determine whether 
uptake of complexed mitochondria by Huh 7 cells had occurred, primers were designed, 
Table 3.1, and shown to amplify HTC (rat) mitochondrial DNA, and specifically 




Huh7 cells incubated with Fl-AsOR-PL–mitochondria complex resulted in a 990-fold 
increase of HTC mitochondrial DNA levels (approximately 6-14 HTC mitochondria per 
cell) compared to untreated cells at 15 min, and an increase to more than double 
(approximately 14-36 HTC mitochondria per cell)  (p<0.001) at 60 min, Figure 3.3A. This 
showed that similar to fluorescence levels, mitochondrial DNA levels also increase with 
time in Huh 7 cells. Huh7 cells incubated with either mitochondria alone or Fl-AsOR 
alone failed to show any significant HTC mitochondrial DNA levels suggesting that 
internalization of Fl-AsOR-PL–mitochondria complex was not random. Pre-incubation of 
cells with an excess free AsOR prior to Fl-AsOR-PL–mitochondria complex resulted in 
HTC mitochondrial DNA levels in Huh 7 cells that were 76% lower than in cells 
incubated with complexes without excess AsOR further suggesting that internalization 
of Fl-AsOR-PL–mitochondria complex was AsGR mediated. In contrast, HTC 
mitochondrial DNA levels in SK Hep1 cells were barely detectable under any condition, 
Figure 3.3B. The data suggested that complexed mitochondria were taken up by Huh 7 
cells specifically through the AsGR, and not due to some non-specific interaction. 
Collectively, these data suggest that Huh 7 cells could bind and internalize Fl-AsOR-
PL–mitochondria complexes through AsGR mediated endocytosis. These complexes 





FIGURES AND TABLES 
Table 3.1. Sequences of Primers Used For Quantification 
Primers Sequences 
LDHA FW 5’-TAATGAAGGACTTGGCAGATGAACT-3’ 
LDHA RV 5’-ACGGCTTTCTCCCTCTTGCT-3’ 
HTC Mito FW 5’-AGGCTTAAAAGCAGCCATCA-3’ 
HTC Mito RV 5’-GACAATGGTTATCCGGGTTG-3’ 
Huh 7 Mito FW 5’-CCTGACTCCTACCCCTCA-3’ 
Huh 7 Mito RV 5’-ATCGGGTGATGATAGCCAAG-3’ 
 





Figure 3.1. Primer specificity for mitochondrial DNA by amplification. 
Primers were designed using Primer 3 and Primer-BLAST to amplify Huh7 
mitochondrial DNA or HTC and rat liver mitochondrial DNA specifically. Cell 







       
Figure 3.2. Uptake of Fl-AsOR-PL–mitochondria complexes as measured by 
fluorescence. 
Cells were incubated with Fl-AsOR-PL–mitochondria complex, mitochondria alone, Fl-
AsOR alone or excess AsOR + complex at 37°C. At 15 min and 60 min, cells were 
collected and fluorescence levels measured by a fluorescence spectrophotometer. A, 




      
 
Figure 3.3. Uptake of Fl-AsOR-PL–mitochondria complexes as measured by qPCR. 
Cells were incubated with Fl-AsOR-PL–mitochondria complex, mitochondria alone, Fl-
AsOR alone or excess AsOR + complex at 37°C. At 15 min and 60 min, cells were 
collected to measure HTC mitochondrial DNA in Huh 7 and SK Hep1 cells compared to 




CHAPTER 4: EFFECTS OF ENDOSOMAL DISRUPTION 
AGENTS ON INTRACELLULAR LOCALIZATION OF TARGETED 
MITOCHONDRIA 
AsGR-mediated endocytosis is known to be a degradative pathway. Therefore, 
mitochondria internalized by Huh 7 cells were expected to be digested by lysosomal 
enzymes. Release of internalized mitochondria by hepatocytes into the cytoplasm 
should occur before exposure to lysosomal contents; otherwise internalization would not 
be helpful to develop a potential therapy for mitochondrial dysfunctional disorders. A 
number of microbes including viruses, and especially bacteria have evolved systems by 
which endosomes, into which they are endocytosed, are induced to rupture (See 
Chapter 1). 
 
LISTERIOLYSIN O (LLO) FACILITATED ENDOSOMAL ESCAPE 
Bacteria, Listeria monocytogenes produces a cholesterol-dependent toxin listeriolysin O 
(LLO) which gets activated at low pH and in reducing conditions that exist in 
endosomes, and induces pore formation in the cholesterol-containing membranes [317]. 
The pores result in influx of aqueous cytoplasmic content due to an osmotic gradient, 
and eventually rupture of endosomes resulting in escape of the bacteria, and 
endosomal contents into the cytoplasm [318, 319].  Because of its pH-dependent 
activity and rapid degradation in cytosol, cytotoxic effects of LLO are potentially reduced 
[271, 320]. LLO has been used as an endosomal escape agent alone [293] or in 




LLO along with Fl-AsOR-PL–mitochondria for targeted delivery to hepatocytes. Because 
it is known that the simultaneous binding of many AsGR is required to trigger 
endocytosis, it is possible that mitochondria and LLO could be targeted to the same 
endosome. Such a co-internalization event could result in endosomal escape and 
cytoplasmic delivery of targeted molecules to hepatocytes [293] (Figure 1.3). 
 
AsOR-LLO CONJUGATES 
To facilitate endosomal escape and intra-cytoplasmic delivery of mitochondria, 
advantage was taken of a bacterial protein, listeriolysin O (LLO), which is known to 
produce pores in endosomal membranes under the acidic and reducing conditions that 
exist in endosomes.  
Conjugation of LLO to AsOR could result in targeting of the protein to hepatocytes. Co-
internalization of the LLO-conjugate could result in rupture of endosomes, endosomal 
escape, and intracytoplasmic delivery of mitochondria (Figure 1.3). An irreversible 
linkage between AsOR and LLO might interfere with the ability of LLO to interact with 
the endosomal membranes after internalization to form pores. Therefore, an AsOR-LLO 
conjugate was prepared by chemically coupling AsOR to LLO using an SPDP cross-
linker (N-succinimidyl 3-(2-pyridyldithio) propionate). The SPDP cross-linkers produce 
disulfide-containing linkages between protein molecules that can be cleaved later with 
reducing agents such as dithiothreitol (DTT) (Figure 4.1). These disulfide bonds would 




internalization. Stability of the conjugate and release of LLO from AsOR under reducing 
conditions was demonstrated in vitro, Figure 4.2 and Table 4.1.  
LLO is a membranolytic protein and could cause potential damage to outer membrane 
of isolated mitochondria leading to exposure of cytochrome c oxidase on inner 
membrane of mitochondria. Activity of cytochrome c oxidase was measured in 
mitochondria incubated with LLO and AsOR-LLO conjugate under different conditions to 
determine the damage to outer membrane of isolated mitochondria.  
Activity of membranolytic proteins can also be measured with hemolytic assays where 
proteins are incubated with red blood cells (RBCs) to determine the membranolytic 
activity of proteins. Hemolytic assays were performed with LLO and AsOR-LLO 
conjugates under different conditions to determine their hemolytic activities.  
Uptake assays were performed with and without AsOR-LLO conjugates for different 
time periods to determine change in internalization with time. To determine 
internalization was AsGR mediated; cells were pre-incubated with excess free AsOR to 
compete with internalization of Fl-AsOR-PL–mitochondria complex. After uptake 
assays, internalization of the protein carrier, Fl-AsOR-PL was determined by measuring 
fluorescence intensity in cells. Uptake of HTC mitochondria by human hepatocytes was 
measured by qPCR (See Chapter 3). 
The specificity of AsGR-mediated internalization of mitochondrial complexes in 
presence of AsOR-LLO conjugates by hepatocytes was also determined by uptake 




EFFECTS OF COLCHICINE TREATMENT  
Colchicine is a toxic drug used to treat gout [323], pericarditis [324] and several other 
diseases. Colchicine treatment inhibits microtubule polymerization in cells by binding to 
tubulin [325]. Hence, colchicine induced impaired microtubule formation and restrained 
cytoskeletal movements in cells inhibits endocytosis [326]. Colchicine treatment of 
hepatocytes would allow recognition and binding of AsGs to AsGR on cell surface, but 
hindered endosomal formation would inhibit internalization of the ligand-receptor 
complexes. Therefore, cells were treated with colchicine prior to uptake of Fl-AsOR-PL–
mitochondria complexes with or without AsOR-LLO conjugates to determine non-
specific association of Fl-AsOR-PL–mitochondria complexes on cells surface. 
 
EFFECTS OF LOW TEMPERATURES ON CELL MEMBRANES 
A number of factors can affect cell membrane fluidity. Variations in temperature can 
cause changes in fluidity of cell membranes [327]. At low temperatures viscosity of 
plasma membranes increase and hence fluidity decreases which further hinders 
endosomal formation on cell surfaces. This allows recognition and binding of AsGs to 
AsGR on cell surface, but inhibits internalization of the ligand-receptor complexes. 
Henceforth, uptake assays of Fl-AsOR-PL–mitochondria complexes with or without 
AsOR-LLO conjugates at low temperatures would help to determine non-specific 
association of Fl-AsOR-PL–mitochondria complexes on hepatocytes surface.   
To determine to localization of internalized AsOR-PL–mitochondria complexes by 




After uptake of AsOR-PL–mitochondria complexes with or without AsOR-LLO 
conjugates, cells were labeled with early endosomal markers and localization of early 
endosomes and internalized mitochondria was observed under confocal microscope. 
Co-localization of early endosomes and GFP-labeled mitochondria in Z-axis of cell was 
also determined. Intensities of both early endosomal marker and GFP-labeled 
mitochondria in each stack of the image was measured and plotted against stack 
number of the image. Higher intensities from both labels in same stacks would 
determine co-localization of early endosomes and GFP-labeled mitochondria in Z-axis 











PREPARATION OF TARGETABLE LLO 
Wild type (WT) listeriolysin O (LLO) was purified from a hypersecretor strain of L. 
monocytogenes, a generous gift from D. A. Portnoy, Stanford University, by a method 
described previously [328] with a modification that supernatants were concentrated 
using centrifugal devices (EMD Millipore Centricon® Plus-70 Centrifugal Filter Units, 
Membrane NMWL 30,000), washed with 3 L ice-cold distilled water, and concentrated to 
400-600 ml. Supernatants were  passed through a DEAE-Sephacel column, and 
purified LLO was washed, and then desalted with PD-10 columns (Sephadex G-25 M, 
Pharmacia Biotech). Purified LLO was aliquoted and stored at -20°C until further use. 
AsOR-LLO conjugates were synthesized using an SPDP cross-linker (Thermo 
Scientific) according to manufacturer’s instructions. In brief, 1 mg of AsOR and LLO 
were dissolved in 12 µl of 20 mM SPDP and incubated separately at 25°C for 60 min. 
Preparations were desalted with PD-10 columns equilibrated with PBS. LLO-SPDP was 
reduced with DTT, and desalted on a PD-10 column equilibrated with PBS. Reduced 
LLO-SPDP (1 mg in 2.5 ml PBS) was mixed with AsOR-SPDP (1 mg in 2.5 ml PBS), 
and incubated for 18 h at 4°C to form AsOR-LLO conjugate.  The conjugate was purified 
and concentrated using centrifugal devices (EMD Millipore Centricon® Plus-70 
Centrifugal Filter Units, membrane NMWL (Nominal Molecular Weight Limit) 50,000).  
Final concentrations of proteins were measured using a Bio-Rad protein assay (BIO 
RAD) according to manufacturer’s instructions. Purity and size of proteins was 




Coomassie R250 (Sigma) in 10% acetic acid, 20% methanol and de-stained in 10% 
acetic acid, 20% methanol. 
CYTOCHROME C OXIDASE ASSAY 
LLO is known to cause pores in membranes, and because mitochondria are membrane-
limited organelles, we sought to determine whether LLO would damage mitochondrial 
membranes. Effects on the integrity of the outer membrane of isolated mitochondria 
were assessed by measuring cytochrome C oxidase activity. LLO and AsOR-LLO 
conjugate were incubated separately with isolated HTC mitochondria with or without 
DTT at pH 7.5 and pH 5.6 for 45 min at 37°C. Cytochrome c oxidase activity was 
assayed by a kit (CYTOCOX1, Sigma-Aldrich) and the % cytochrome C oxidase activity 
relative to untreated controls was calculated according to manufacturer’s instructions. 
HEMOLYSIS 
While, the gel showed cleavage under conditions known to exist in endosomes, a better 
measure of membranolytic activity is to measure hemolysis. To determine hemolytic 
activity, [293, 329], varying concentrations of LLO and AsOR-LLO conjugate were 
incubated, with or without DTT, with approximately 5 million human RBCs in 10 µl PBS 
separately at pH 7.4 and pH 5.6 for 30 min at 37°C. Effects of cholesterol on hemolytic 
activity were determined as described previously [330]. Samples were spun at 3000 rpm 
for 5 min, and absorbance of supernatants measured at 540 nm. The amounts of 
protein required for 50% hemolysis (50% complement hemolytic (CH50) activity) were 
calculated [331]. Assays were performed in 4 independent replicates, and the results 





To create GFP-labeled mitochondria, HTC cells were transfected with pAcGFP1-Mito 
plasmid (Clontech Laboratories) using lipofectamine (Life Technologies) according to 
manufacturer’s instructions. pAcGFP1-Mito plasmid encodes a mitochondrial targeting 
sequence (derived from the precursor of subunit VIII of human cytochrome C oxidase) 
fused to N-terminus of green fluorescent protein (GFP) from Aequorea coerulescens 
(AcGFP). Fluorescence-activated cell sorting (FACS) was used to separate GFP-
labeled cells to make a stable cell line (Figure 4.8). HTC mito-GFP cells were 
maintained in DMEM supplemented with antibiotic/antimycotic solution, 10% FBS and 
1.5 mg/ml G418 (Calbiochem). GFP-labeling was determined using MitoTracker RED 
FM (Molecular Probes - Life Technologies) according to the manufacturer’s instructions. 
In brief, 200 nM MitoTracker red probe in Opti-MEM I medium (Invitrogen) was 
incubated with HTC mito-GFP cells for 30 min. Cells were washed twice PBS, fixed with 
4% paraformaldehyde and washed 4 times with PBS. Labeled cells were mounted in 
ProLong® Gold reagent (Life Technologies), and used for fluorescent microscope 
imaging. 
UPTAKE ASSAY 
Uptake assays were performed as described in Chapter 3, Methods.  Mitochondria were 
isolated from donor cells (HTC or HTC mito-GFP cells). Uptake assays were conducted 
at 37°C or 4°C in DMEM, 2.8 mM Ca2+ [312] to which was added 25 µl/ml Fl-AsOR-PL–
mitochondria complex, 25 µl/ml Fl-AsOR-PL–mitochondria complex + 0.15 µg/ml AsOR-




fold molar excess added 4 min prior to uptake) or 25 µl/ml Fl-AsOR-PL–mitochondria 
complex + 0.15 µg/ml AsOR-LLO conjugate + 200 µg/ml AsOR (100-fold molar excess 
added 4 min prior to uptake). Assays were repeated with 3 independent replicates. 
To determine the effects of colchicine on mitochondrial uptake, cells were incubated 
with 1 µM colchicine for 2 h prior to uptake and during the uptake assay [326]. To 
determine the effects of low temperature on mitochondrial uptake, studies were also 
performed at 4°C using ice cold phosphate- and bicarbonate-free DMEM. 
CONFOCAL MICROSCOPY 
To determine the intracellular localization of targeted mitochondria in cells, Huh 7 cells 
were plated at 50% confluence, on sterile cover slips in 6-well tissue culture plate 
(Sigma). Cells were washed with PBS (Mg2+-and Ca2+ -free) and maintained in 
supplement-free phosphate-free DMEM with high glucose (Life Technologies, #11971) 
for 16 h followed by exposure to AsOR-PL-mito-GFP complex, mito-GFP, and AsOR-
PL-mito-GFP complex + AsOR-LLO conjugate separately for 2 h at 37°C. Cells were 
washed with EDTA-PBS and maintained in DMEM supplemented with 
antibiotic/antimycotic solution, and 10% FBS for 6 h. Cells were fixed with 4% 
paraformaldehyde for 30 min, and permeabilized with 0.25% Triton X-100 (Sigma) in 
PBS for 10 min followed by blocking solution (1% goat serum, 5% BSA, 0.3 M glycine) 
for 1 h at 25°C. Cells were incubated with anti-EEA1 antibody [1G11] (early endosome 
marker from Abcam Inc, #ab70521) overnight at 4°C. Alexa fluor 594 goat anti-mouse 
(Life Technologies) secondary antibody was added for 1 h. Nuclei were stained with 




microscope, and images were analyzed with Image J for the presence of early 
endosomes (red), mitochondria (green), and nuclei (DAPI), and early endosomes and 
mitochondria merged (yellow). 
To determine the localization of endosomes and mitochondria in the Z-plane, areas 
were randomly selected on the images taken by confocal microscopy. For each 
selected area, GFP and Alexa fluor 594 intensities were measured from each slice of Z-
stacks of the image, and plotted together against the slice number of the image. High 
fluorescence intensity of both GFP and Alexa fluor 594 in close proximity were 







RESULTS AND DISCUSSION 
AsOR-LLO conjugates were made using SPDP cross-linkers (Figure 4.1). Proteins 
alone and conjugate were run on SDS-PAGE to determine approximate masses and 
purity. Figure 4.2 shows that AsOR runs around as 37 kDa and LLO around 50 kDa. 
The AsOR-LLO conjugate preparation did not contain free LLO or AsOR, but did have 
two bands, one at about 74 kDa, a position expected for AsOR-LLO. The higher mass 
band at about 90 kDa could be an LLO-dimer. Exposure of the conjugate preparation to 
reducing conditions, i.e. DTT, caused both bands to disappear, and the return of bands 
corresponding to AsOR and LLO, Figure 4.2. This showed that an AsOR-LLO conjugate 
was formed which was cleavable under reducing conditions. 
Cytochrome C assays with LLO show some damage to outer membrane of 
mitochondria at pH 7.5 which increased at pH 5.6. Damage became significantly high in 
presence of DTT. Whereas AsOR-LLO conjugate did not affect the mitochondrial outer 
membrane and expose cytochrome c on the inner membrane of mitochondria, Figure 
4.3 at pH 7.5 or 5.6 in absence of DTT. This suggested that AsOR-LLO conjugates 
would not cause damage to outer membrane of mitochondria while performing uptake 
assay. LLO should be released in an endosomal environment where it could facilitate 
the release of complexes in cytoplasm.  
Using hemolysis as a measure of membrane-disruptive activity, LLO alone at pH 5.6 
resulted in hemolysis of 32.8% of red blood cells. This increased to 88.6% in the 
presence of a reducing agent, DTT (p<0.0001).  In contrast, AsOR-LLO conjugate had 
no hemolytic activity in the absence of DTT at pH 7.4 or pH 5.6, but had 32.7% activity 




the activity of both LLO and LLO-AsOR complex, Table 4.1, which was consistent with 
membranolytic properties of LLO. This further suggested that cleavage of LLO from 
AsOR-LLO conjugate was required for its membranolytic activity. 
To determine whether the AsOR-LLO conjugate could affect intra-cytoplasmic delivery 
of mitochondria to hepatocytes, uptake assays were performed with Huh 7 cells and SK 
Hep1 cells at 37°C with or without AsOR-LLO conjugates. After incubation with Fl-
AsOR-PL–mitochondria complex alone, fluorescence levels in Huh 7 cells were 13,400 
units at 15 min which increased to more than 30,000 units at 120 min, Figure 4.4A. 
However, co-administration of AsOR-LLO conjugate with complexed mitochondria led to 
an increase in fluorescence levels in Huh 7 cells from 13,000 units at 15 min to 
approximately 50,000 units at 120 min (p<0.0001). This suggested that internalization of 
protein carrier was time-dependent, and increased in presence of AsOR-LLO. Pre-
incubation of a large molar excess of AsOR for competition resulted in a >90% 
decrease in fluorescence in Huh 7 cells exposed to complexed mitochondria with or 
without AsOR-LLO. SK Hep1 cells did not show significant levels of fluorescence under 
any condition at any time point, Figure 4.4B which further suggested that internalization 
of protein carrier was AsGR mediated. 
In addition to increased fluorescence levels, co-administration of AsOR-LLO conjugate 
with complexed mitochondria also resulted in increased HTC mitochondrial DNA levels 
in Huh 7 cells from 110-fold (approximately 1-2 HTC mitochondria per cell) at 15 min to 
approximately 23,800-fold (approximately 136-343 HTC mitochondria per cell) over 
untreated controls approximately at 120 min, Figure 4.5A. However, incubation of Fl-




from 690-fold (approximately 4-10 HTC mitochondria per cell) at 15 min to 7500-fold 
(approximately 43-107 HTC mitochondria per cell) over untreated controls at 120 min in 
Huh 7 cells (p<0.001). This suggested that similar to the protein carrier, internalization 
of mitochondria was time-dependent and increased in presence of AsOR-LLO. Pre-
incubation of excess free AsOR decreased HTC mitochondrial DNA levels by >75% in 
Huh 7 cells exposed to complexed mitochondria with or without AsOR-LLO. No 
significant levels of HTC mitochondrial DNA were found in SK Hep1 cells under any 
condition, Figure 4.5B. This further suggested that internalization of complexes was 
AsGR mediated. 
For further confirmation that the observed levels of HTC mitochondrial DNA in Huh 7 
cells had resulted from entry into the cells by receptor-mediated endocytosis, cells were 
pre-treated with colchicine for 120 min. Colchicine inhibits endocytosis and hinders 
internalization. The amount of HTC mitochondrial DNA associated with these cells was, 
2,100-fold (approximately 13-29 HTC mitochondria per cell) over untreated controls at 
120 min Figure 4.6, which was significantly lower than in Huh 7 cells not pre-treated 
with colchicine (p<0.00001). This suggested that higher levels of mitochondrial DNA 
observed in Huh 7 cells exposed to Fl-AsOR-PL–mitochondria complexes and AsOR-
LLO conjugates in non-colchicine treated cells were not because of ‘non-specific’ 
association. 
 In addition, endocytosis is also inhibited at 4°C because of deceased fluidity of plasma 
membrane. Uptake in Huh 7 cells at 4°C showed no significant levels of HTC 
mitochondrial DNA at any time point, Figure 4.7. This further suggested that higher 




To determine the localization of internalized mitochondria, a cell line stably expressing 
GFP-labeled mitochondria, HTC mito-GFP cells were used (Figure 4.8) (See Chapter 
1). Cells were stained with MitoTracker RED, which intercalates between 
intermembrane space of mitochondria. Co-localization of mito-tracker red staining 
mitochondria and GFP in HTC mito-GFP cells showed that mitochondria were labeled 
with GFP (Figure 4.9). HTC mito-GFP cells were used as source for GFP labeled 
mitochondria. GFP-labeled mitochondria were isolated, and complexes were with 
AsOR-PL were made as described in Chapter 2, Methods. AsOR-PL–mitochondria 
complexes and controls were incubated for 120 min with Huh 7 cells. Six h later, cells 
were stained with an endosomal marker (EEA1- Alexa Fluor 594). Huh 7 cells incubated 
with GFP-labeled HTC mitochondria showed endosomal (red) staining, Figure 4.10A1, 
but no GFP staining was observed, Figure 4.10B1. Cells incubated with AsOR-PL–
mitochondria complex showed endosomal staining; Figure 4.10A2, but little GFP, Figure 
4.10B2. Most of the GFP-stained structures were overlapping Alexa Fluor 594 in the 
merged view (yellow), Figure 4.10D2, suggesting co-localization of mitochondria and 
endosomes. Co-localization of GFP and Alexa Fluor 594 was supported by 
fluorescence plot intensities in Z-axis of cell images from random fields, Figure 4.11. 
Higher intensities of both GFP and Alexa Fluor 594 in same stacks of image suggest 
that both GFP-labeled mitochondria and endosomes co-localize. Cells incubated with 
both AsOR-PL–mitochondria complex and AsOR-LLO conjugate also showed 
endosomal vesicles, Figure 4.10A3, and many GFP- and Alexa Fluor 594-stained 
punctate structures, Figure 4.10D3. However, most GFP structures remained green in 




mitochondria not co-localized with endosomes. These data supported conclusion that 
co-administration of AsOR-LLO and complexed mitochondria resulted in escape of HTC 
mitochondria from endosomes. Internalization was not found uniform in all cells, which 
might be because of differential expression of AsGR in hepatocytes based on many 





FIGURES AND TABLES 
 
 
Figure 4.1. A diagram of a targetable AsG–LLO conjugate cleavable under reducing 
conditions. 
AsOR and LLO were coupled with a disulfide linker to form an AsOR-LLO conjugate 





Figure 4.2. SDS-PAGE of AsOR-LLO conjugate and components stained with 
Coomassie Brilliant Blue. 
Proteins were run on a 10% SDS-PAGE and stained with Coomassie blue. Lanes: 1, 







































Figure 4.3. Cytochrome C oxidase assay. 
Mitochondria were incubated with LLO and AsOR-LLO conjugate at pH 7.5 or 5.6, with 
or without DTT for 45 min, and damage to outer membrane of mitochondria was 
measured by quantitation of the amount of ferrocytochrome c oxidized to 















Figure 4.4. Changes in fluorescence after co-administration of complexed mitochondria 
and AsOR-LLO conjugates in cells. 
Cells were incubated separately with Fl-AsOR-PL–mitochondria complex, complexed 
mitochondria and AsOR-LLO conjugates, excess AsOR + complexed mitochondria or 
excess AsOR + complexed mitochondria + AsOR-LLO conjugates at 37°C. At 15 min, 
60 min and 120 min, cells were collected to measure fluorescence. A, Huh 7 cells; B, 







Figure 4.5. HTC mitochondrial DNA levels in cells after exposure to complexed 
mitochondria and AsOR-LLO conjugates. 
Cells were incubated separately with Fl-AsOR-PL–mitochondria complex, complexed 
mitochondria and AsOR-LLO conjugates, complexed mitochondria + excess AsOR, or 
complexed mitochondria + AsOR-LLO conjugates + excess AsOR at 37°C. At 15, 60 
and 120 min, cells were collected and HTC mitochondrial DNA levels measured by 





Figure 4.6. HTC mitochondrial DNA levels in colchicine-treated Huh 7 cells after 
exposure to complexed mitochondria and AsOR-LLO conjugates. 
Huh 7 cells were treated with 1 µM colchicine for 2 h prior and during exposure to Fl-
AsOR-PL–mitochondria complex, complexed mitochondria and AsOR-LLO conjugates, 
complexed mitochondria + excess AsOR or complexed mitochondria + AsOR-LLO 
conjugates + excess AsOR at 37°C. At 15, 60 and 120 min, cells were collected and 








Figure 4.7. HTC mitochondrial DNA levels in Huh 7 cells at 4°C after exposure to 
complexed mitochondria and AsOR-LLO conjugates. 
Huh 7 cells were incubated separately with Fl-AsOR-PL–mitochondria complex, 
complexed mitochondria and AsOR-LLO conjugates, complexed mitochondria + excess 
AsOR or complexed mitochondria + AsOR-LLO conjugates + excess AsOR at 4°C. At 
15, 60 and 120 min, cells were collected and HTC mitochondrial DNA measured by 








Figure 4.8. Isolation of an HTC mito-GFP cell line by fluorescence-activated cell sorting 
(FACS). 
HTC cells stably expressing GFP-labeled mitochondria were sorted with FACS to 
establish an HTC mito-GFP cell line which was subsequently maintained in 1.5 mg/ml 







Figure 4.9. HTC Mito-GFP cells stained with Mito-Tracker Red. 
HTC mito-GFP cells were incubated with MitoTracker red probe for 30 min, washed, 







Figure 4.10. Localization of early endosomes and GFP-labeled HTC mitochondria by 
confocal fluorescence microscopy. 
Huh 7 cells were incubated separately with GFP-mitochondria alone, AsOR-PL–GFP-
mitochondria complex, or co-administered with complexed GFP-mitochondria and 
AsOR-LLO conjugates at 37°C for 2 h. Cells were washed with PBS and maintained in 
DMEM for 6 h before fixing with paraformaldehyde and staining for early-endosome 
marker EEA1. Cells were imaged under confocal fluorescence microscope. Panels A1-
A3, endosomal marker (anti-EEA1-Alexa 594, red); B1-B3, GFP (green); C1-C3, DAPI 






Figure 4.11. A plot of fluorescence intensities of confocal microscopic images versus 
stack number. 
A plot of fluorescence intensities of early endosomal marker EEA1 and GFP-
mitochondria, and stack number of confocal microscopic images of Huh 7 cells, 6 h post 










CHAPTER 5: ASSESSMENT OF FUNCTION AND STABILITY 
OF MITOCHONDRIA TARGETED TO HEPATOCYTES LACKING 
MITOCHONDRIA 
Being metabolically highly active, liver cells require high number of mitochondria to 
meet their energy needs. Damage to mitochondria in liver cells can result in severe liver 
dysfunction and eventually liver failure. The common effect of most mitochondrial 
disorders is insufficient energy production. Delivery of healthy and functional 
mitochondria to hepatocytes with damaged mitochondria may allow the cells to recover 
from such damage. 
The objective of this study was to determine whether healthy and functional 
mitochondria could be delivered to hepatocytes with damaged mitochondria. Previous 
data, in this study, suggested that mitochondria can be internalized by hepatocytes 
through AsGR mediated endocytosis and escape from endosomes can be facilitated 
with hemolytic activity of LLO. Delivery of mitochondria to hepatocytes would be useful 
only if internalized mitochondria are stable and functional in hepatocytes, and could 
provide survival advantage to affected cells. A model (mitochondrial DNA free Huh 7-
mito (-) and SK Hep1-mito (-) cells) for mitochondrial hepatopathies was developed by 
treating Huh 7 and SK Hep1 cells with ddC to deplete mitochondrial DNA levels in cells 
(See Chapter 1), Figure 5.1. Assays were performed to determine whether mitochondria 
could be targeted to Huh 7-mito (-) and SK Hep1-mito (-) cells.  
Mitochondrial damage caused decreased energy levels in Huh 7-mito (-) and SK Hep1-




determine if cells can still recognize and internalize AsGs, uptake assays with Fl-AsOR 
were performed.  
Because of the lack of mitochondria, these cells required special supplemental media 
containing compensatory nutrients to permit survival, Figure 5.2. Withdrawal of the 
required special supplemental media containing compensatory nutrients results in death 
of the cells. Therefore, survival of cells in supplement-free media after exposure to 
complexed mitochondria could indicate appropriate mitochondrial function after 
internalization. Survival in mitochondria free cells was observed for long periods of time 
after exposure to Fl-AsOR-PL–mitochondria complexes with or without AsOR-LLO 
conjugates and other controls (See Chapter 3), Stability of mitochondrial DNA levels in 
Huh 7-mito (-) and SK Hep1-mito (-) cells for long periods of time was also observed to 
determine long term stability of internalized mitochondria. 
Functional stability of mitochondria in Huh 7-mito (-) and SK Hep1-mito (-) cells could be 
determined by determining the mitochondrial respiration in targeted cells. Since 
endogenous mitochondria of cells have depleted mitochondrial DNA and hence non-
functional, stable mitochondrial respiration in mitochondrial DNA free cells exposed to 
Fl-AsOR-PL–mitochondria complexes with or without AsOR-LLO conjugates and other 






Mitochondria undergo aerobic respiration which requires oxygen in order to generate 
ATP [332]. The outer membranes of mitochondria contain many complexes of integral 
membrane proteins that form channels through which a variety of molecules and ions 
move in and out of the mitochondria [333]. The inner membranes of mitochondria 
contain five complexes of integral membrane proteins as part of respiratory complex; 
NADH dehydrogenase (Complex I); succinate dehydrogenase (Complex II), cytochrome 
c reductase (Complex III; also known as the cytochrome b-c1 complex), cytochrome c 
oxidase (Complex IV); ATP synthase (Complex V) [334, 335]. Complexes I, III and IV 
constitutes the electron transport chain (ETC) of mitochondria [336, 337] and where 
stepwise shuttling of electrons from NADH (or FADH2) to oxygen molecules with the 
help of two freely-diffusible molecules, ubiquinone and cytochrome c [338], form (with 
the aid of protons) water molecules [339]. ETC couples energy released by electron 
transfer to the pumping of protons (H+) from the matrix to the intermembrane space. 
The gradient of protons formed across the inner membrane by this process of active 
transport stores high amounts of intermediate energy [340]. The protons can flow back 
down this gradient only by re-entering the matrix through ATP synthase (complex V) in 
inner membrane [341]. The energy released as these protons flow down their gradient 
is coupled to the synthesis of ATP [342, 343] and the process is called oxidative 
phosphorylation (or OXPHOS) [344]. This allows the production of large amount of ATP 
supply of cells by mitochondria. Measurement of oxygen consumption rates (OCR) from 
cells or isolated mitochondria is useful to evaluate the mitochondrial stress, dysfunction 




respiration or OXPHOS [345]. Several valuable methods are available in research to 
measure OCR in mitochondria like set of ETC complex inhibitors [346]. 
Several types of respiratory inhibitors for complexes of ETC in mitochondria have been 
identified. Inhibitors act by binding one or more electron carriers, preventing electron 
transport directly. An inhibitor may completely block electron transport by irreversibly 
binding to a binding site (example cyanide [347]) or bind competitively (example 
rotenone [348]). Injections of these inhibitors to cells result in inhibition of different 
complexes of ETC and hence OCR.  
For mitochondrial stress assays, OCR is measured before and after the addition of a 
series of three different inhibitors to cells or isolated mitochondria. OCR measured 
before addition of inhibitors represents the basal respiration of cells.  
Initially, addition of oligomycin, a complex V inhibitor, results in blocking of proton 
channels, and hence results in decreased electron flow [349]. This results in decreased 
OCR, which can be used to calculate ATP-linked respiration (by subtracting the 
oligomycin rate from baseline cellular OCR) and proton leak respiration (by subtracting 
non-mitochondrial respiration from the oligomycin rate). 
Addition of a protonophore, carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon 
(FCCP), collapses the inner membrane gradient [350], and disrupts the mitochondrial 
inner membrane potential. This allows free flow of electrons across the membrane and 
ETC to function at its maximal rate increasing OCR to maximum in mitochondria. This 
allows calculating maximal respiratory capacity of mitochondria by subtracting non-




Lastly, addition of antimycin A and rotenone, inhibitors of complex III and I [351, 352] 
shuts ETC function down, and leads to complete inhibition of oxygen consumption by 
mitochondria. Resulting OCR is from non-mitochondrial respiration. Mitochondrial 
reserve capacity can be estimated by subtracting basal respiration from maximal 
respiratory capacity. These fluctuations in OCR on addition of these inhibitors determine 
the mitochondrial stress and disorders. 







PREPARATION OF MITOCHONDRIA (-) CELLS 
To create a model of cells lacking mitochondria, Huh 7 and SK Hep1 cells were seeded 
at 20% confluence, and the exposed to 10 µM 2’, 3’-dideoxycytidine (ddC) (Sigma-
Aldrich #5782) for 3 weeks [120]. Cells were maintained in DMEM supplemented with 
antibiotic/antimycotic solution, 10% dialyzed FBS, 2 mM L-glutamine, 100 mg/ml sodium 
pyruvate (Invitrogen), and 50 mg/ml uridine (Sigma) [299]. Mitochondrial DNA levels 
were determined with qPCR periodically and cells lacking detectable mitochondrial DNA 
were considered to be mito (-). Huh 7-mito (-) and SK Hep1-mito (-) cells were frozen at 
-80°C until needed. 
CELL PROLIFERATION ASSAY 
Huh 7-mito (-) and SK Hep1-mito (-) cells were plated at 90% confluence, 2 days before 
uptake assay on 24-well tissue culture plate (Sigma). Equal numbers of Huh 7 and SK 
Hep1 cells were plated on 6-well tissue culture plates (Sigma). Cells were washed with 
PBS (Mg2+-and Ca2+ -free) and maintained in supplement-free, phosphate-free DMEM 
with high glucose (Life Technologies, #11971) for 2 h followed by exposure to 
complexed mitochondria or controls for 2 h. Media containing complexed mitochondria 
were removed, and cells were washed with PBS (Mg2+-and Ca2+ -free), and then 
maintained in supplement-free DMEM with antibiotic/antimycotic solution, and 
containing 1% dialyzed FBS. DNA levels were determined at various time points using a 
CyQUANT Cell proliferation assay kit (Molecular probes, Life technologies) according to 




fluorescence at 520 nm were generated, and used to calculate DNA concentrations. 
Experiments were conducted in triplicate, and repeated twice. Results are expressed as 
mean ± standard error of total cellular DNA, (ng/well) per group. Cell cultures were not 
split at any time. 
MITOCHONDRIA RESPIRATION ASSAYS 
Huh 7-mito (-) cells were plated at 90% confluence in XF24 cell culture microplates 
(Seahorse Bioscience) 2 d before uptake assays. Cells were washed with PBS (Mg2+-
and Ca2+ -free) and maintained in supplement-free, phosphate-free high glucose DMEM 
(Life Technologies, #11971) for 2 h before uptake. Complexed mitochondria and 
controls were incubated with cells in the same media for 2 h. Cells were changed to 
supplement-free DMEM with antibiotic/antimycotic solution, 1% dialyzed FBS after 
uptake for 2 h, and respiration assays were performed using an XF Cell Mito Stress Kit 
(Seahorse) at various time points with Seahorse XFe Analyser according to 
manufacturer’s instructions. Oxygen consumption rate (OCR) per well normalized to 
DNA levels were determined.  Assays were performed in triplicate, and results are 
expressed as mean ± standard error of OCR per group in units of pmol/min/DNA level 
at each time point. Huh 7 cells, positive controls, were plated 90% confluent 2 d before 
each OCR measurement.  
MITOCHONDRIA (-) CELL UPTAKE ASSAY 
Huh 7-mito (-) and SK Hep1 -mito (-) cells were plated 90% confluent 2 d before uptake 
assay. Cells were washed with PBS (Mg2+-and Ca2+ -free) and maintained in 




for 2 h before uptake. Administration of complexed mitochondria and controls were 
performed as described in Chapter 4, Methods. Cells were maintained in supplement-
free DMEM with antibiotic/antimycotic solution, 1% dialyzed FBS after uptake. Cells 
were collected at various time points for measurement of fluorescence and 






RESULTS AND DISCUSSION 
Treatment of Huh 7 and SK Hep1 cells with ddC resulted in undetectable mitochondrial 
DNA after approximately 3 weeks, Figure 5.1. This indicated that in Huh 7-mito (-) and 
SK Hep1-mito (-) cells have dysfunctional mitochondria, and could be useful as study 
models of mitochondrial hepatopathies. Removal of supplements in cell culture media 
resulted in decreased cellular DNA in Huh 7 mito (-) and SK Hep1 mito (-) cells with 
time, whereas parental Huh 7 and SK Hep1 cells showed increased cellular DNA, 
Figure 5.2, indicating that mito (-) cells required supplements in the media for survival.  
Mitochondrial damage in Huh 7-mito (-) and SK Hep1-mito (-) cells resulted in 
decreased energy levels, which affects the cellular activities including endocytosis [353]. 
Exposure of Fl-AsOR, to Huh 7-mito (-) cells resulted in uptake of fluorescence, but 
levels were approximately 20% that of parental Huh 7 cells, Figure 5.3A. Pre-incubation 
of excess AsOR nearly abolished this uptake Figure 5.3A, and as expected SK Hep1-
mito (-) cells did not show any significant levels of internalized Fl-AsOR, Figure 5.3B. 
This suggested that, although significantly decreased, Huh 7-mito (-) cells were still able 
to recognize and internalize AsGs through AsGR mediated endocytosis.  
Exposure of complexed Huh7-derived mitochondria alone to Huh 7-mito (-) cells 
showed that fluorescence levels increased from 6,400 units at 60 min to more than 
11,000 units at 120 min (p<0.01). Increased fluorescence levels in Huh 7-mito (-) cells 
with time showed that cells were able to internalize the protein carrier in complex. 
Further, after co-administration of complexed mitochondria with AsOR-LLO conjugate, 
fluorescence levels in Huh 7-mito (-) cells increased from 14,000 units at 60 min to more 




facilitated the delivery of protein carrier in cytoplasm. Pre-incubation of excess AsOR 
resulted in decreased fluorescence levels >90%, Figure 5.4A indicating that 
internalization of the protein carrier was AsGR-mediated. Fluorescence levels in Huh 7-
mito (-) cells decreased from 7,000 units at 12 h to 300 units by 7 d. Co-administration 
of complexed mitochondria and AsOR-LLO conjugate resulted in fluorescence levels 
that decreased from 27,000 units at 12 h to 11,000 units at 10 d, Figure 5.4B. Pre-
incubation of excess free AsOR resulted in no significant levels of fluorescence in Huh 
7-mito (-) cells after exposure to complexed mitochondria with or without AsOR-LLO 
conjugate. Decreasing levels of fluorescence at later time points in cells indicated 
decreasing levels of protein carrier over a longer period of time which could be 
accounted for by degradation of protein in cells, quenching of fluorescence of proteins in 
cytoplasm or diluted levels of protein with cell division. 
There were no significant fluorescence levels in SK Hep1-mito (-) cells under any 
condition at any time point, Figure 5.5A and 5.5B further indicating that internalization of 
protein carrier in Huh 7-mito (-) cells was AsGR-mediated.  
To determine whether levels of mitochondrial DNA in mitochondrial DNA free cells after 
uptake declined similar to fluorescence levels of protein carrier, Huh 7 mitochondrial 
DNA levels were assayed by qPCR. In contrast to the data on fluorescence, complexed 
mitochondria co-administered in presence of AsOR-LLO conjugate to Huh 7-mito (-) 
cells resulted in an increase in mitochondrial DNA levels from 5,300-fold (approximately 
29-71 mitochondria per cell) over control at 12 h to more than 9,700-fold (approximately 
57-143 mitochondria per cell) (p<0.0001) over control at 7 d, and remained stable 




LLO conjugate, resulted in mitochondrial DNA levels 900-fold (approximately 5-14 
mitochondria per cell) over control at 12 h to barely detectable levels at 24 h, Figure 
5.6A. These data suggest that complexed mitochondria were delivered to cytoplasm of 
Huh 7-mito (-) cells with the help of AsOR-LLO conjugate, and were stable for extended 
periods of time whereas internalized mitochondria in absence of AsOR-LLO conjugate 
were rapidly degraded. Mitochondrial DNA levels in SK Hep1-mito (-) cells were barely 
detectable under any condition at any time point, Figure 5.6B. Together, these results 
suggested that the fate of the fluorescence associated with Fl-AsOR-PL–mitochondria 
complex was different from the fate of mitochondrial DNA. The protein marker gradually 
disappeared while the mitochondrial DNA levels increased with time eventually reaching 
a plateau. This also suggested a separation of the carrier from the mitochondria 
sometime within 8 h after internalization. Internalized mitochondrial DNA in Huh 7 cells 
(Appendix H) also declined over a period of time. 
To determine whether uptake of mitochondria by mito (-) cells affected rates of cell 
proliferation in media lacking supplements, the numbers of cells were assayed by 
cellular DNA levels as a function of time after exposure to complexed mitochondria. 
Figure 5.7A shows that co-administration of complexed mitochondria and AsOR-LLO 
conjugate resulted in an increase in cell number to 3.5-fold over baseline (p<0.001) by 
10 d. In contrast, untreated cells decreased in cell numbers to 0.03-fold over baseline 
(p<0.004). Cells exposed to complexed mitochondria or mitochondria alone also 
showed decreased cell numbers to 0.028-fold over baseline (p<0.004). Pre-exposure to 
excess AsOR before co-administration of complexed mitochondria and AsOR-LLO 




(p<0.004). This indicated that AsOR-LLO conjugate facilitated cytoplasmic delivery of 
mitochondria and delivered mitochondria helped rescuing the cells from cell death in 
absence of required supplements.  
 SK Hep1-mito (-) cell numbers decreased under all conditions, Figure 5.7B. The data 
further suggested that internalization of mitochondria by Huh 7-mito (-) cells was AsGR-
mediated.  
Above assays strongly suggest that targeted mitochondria in presence of AsOR-LLO 
conjugates were delivered in cytoplasm of cells and were stable. To determine whether 
these internalized mitochondria were functional and were able to synthesize ATP in Huh 
7-mito (-) cells, the OCR was measured before and after addition of inhibitors to 
quantitate mitochondrial respiration levels in cells. While Huh 7-mito (-) and SK Hep1-
mito (-) cells showed no measurable mitochondrial respiration, Huh 7 and SK Hep1 cells 
showed higher basal OCR which varied on addition of oligomycin, carbonyl cyanide-p-
trifluoromethoxyphenyl-hydrazone (FCCP) or rotenone in a manner consistent with 
mitochondrial respiration in cells, Figure 5.8. This further indicated that our cell culture 
models of mitochondrial hepatopathies had dysfunctional mitochondria.  
Twelve h after co-administration of complexed mitochondria and AsOR-LLO conjugate 
to Huh 7-mito (-) cells resulted in a 70% increase in OCR compared to controls, Figure 
5.9A (p<0.0001). Exposure to mitochondria alone, complexed mitochondria with or 
without AsOR-LLO conjugate plus excess AsOR did not show any measurable 
mitochondrial respiration, Figure 5.9A. Ten d after co-administration of complexed 




respiration comparable to parental Huh 7 cells, Figure 5.9B (p<0.00001). The data 
indicate that internalized mitochondria were functional, and increased OCR in Huh 7-
mito (-) cells, which became indistinguishable from that of parental cells by 10 d. Taken 
together, the data were consistent with proliferation of mitochondria after introduction 
into mito (-) cells, which can account for the observed rescue of Huh 7-mito (-) cells 





FIGURES AND TABLES 
 
Figure 5.1. Mitochondrial DNA levels in Huh 7 and SK Hep1 cells treated with 
ddC. 
Huh 7 and SK Hep1 cells were treated with ddC for 3 weeks and mitochondrial DNA 






Figure 5.2. Cellular DNA levels (ng/well) of cells in wells after change to 
supplement-free media. 
Cells were grown in supplement containing cell culture media, and then changed to 
supplement-free media. Cellular DNA levels as an estimate of the numbers of cells were 








   
Figure 5.3. Determination of Fl-AsOR uptake in mito (-) cells. 
Uptake of Fl-AsOR was determined by spectrophotometry after incubation for 1 h at 






Figure 5.4. Fluorescence in Huh 7-mito (-) cells after co-administration of 
complexed mitochondria and controls. 
Huh 7 -mito (-) cells were incubated separately with cell culture media, mitochondria 
alone, Fl-AsOR-PL–mitochondria complex, complexed mitochondria and AsOR-LLO, 
complexed mitochondria + excess AsOR or complexed mitochondria + AsOR-LLO + 
excess AsOR at 37°C. After 2 h, cells were washed and maintained in supplement-free 
cell culture media. Cells were collected to measure Fl-AsOR-PL levels taken up with 
spectrophotometer at different time points.  A, Fluorescence levels in cells up to 120 





Figure 5.5. Fluorescence in SK Hep1-mito (-) cells after co-administration of 
complexed mitochondria and controls. 
SK Hep1-mito (-) cells were incubated separately with cell culture media, mitochondria 
alone, Fl-AsOR-PL–mitochondria complex, complexed mitochondria and AsOR-LLO, 
complexed mitochondria + excess AsOR and complexed mitochondria + AsOR-LLO + 
excess AsOR at 37°C. After 2 h, cells were washed and maintained in supplement-free 
cell culture media. Cells were collected to measure Fl-AsOR-PL levels taken up with 
spectrophotometer at different time points.  A, Fluorescence levels in cells up to 120 






Figure 5.6. Mitochondrial DNA levels in mito (-) cells after co-administration of 
complexed mitochondria and AsOR-LLO, and controls. 
Cells were incubated separately with cell culture media, mitochondria alone, Fl-AsOR-
PL–mitochondria complex, complexed mitochondria and AsOR-LLO conjugates, 
complexed mitochondria + excess AsOR or complexed mitochondria + AsOR-LLO + 
excess AsOR at 37°C. After 2 h, cells were washed and maintained in supplement-free 
cell culture media. Cells were collected to measure mitochondrial DNA levels by qPCR 






Figure 5.7. Cellular DNA levels in mito (-) cells after co-administration of 
complexed mitochondria and controls. 
Cells were incubated separately with cell culture media, mitochondria alone, Fl-AsOR-
PL–mitochondria complex, complexed mitochondria and AsOR-LLO conjugates, 
complexed mitochondria + excess AsOR or complexed mitochondria + AsOR-LLO 
conjugates + excess AsOR at 37°C. After 2 h, cells were washed and maintained in 
supplement-free cell culture media. Total cellular DNA was measured in each well.  A, 





Figure 5.8. Characterization of mitochondrial respiration. 
Cells were plated in XF24 cell culture microplates 1 day before mitochondria respiration 
assays. Oxygen consumption rates were measured with a Seahorse XFe Analyser to 









Figure 5.9. Oxygen consumption rates in Huh 7-mito (-) cells after co-
administration of complexed mitochondria and controls. 
Huh 7-mito (-) cells were incubated separately with cell culture media, mitochondria 
alone, Fl-AsOR-PL–mitochondria complex, complexed mitochondria + excess AsOR, or 
complexed mitochondria + AsOR-LLO at 37°C. After 2 h, cells were washed and 
maintained in supplement-free cell culture media for various times. Oxygen 
consumption rates were measured after exposure to various inhibitors of regulators of 




CHAPTER 6: CONCLUSIONS AND SIGNIFICANCE  
The data indicate that covalent linkage of an AsG to PL forms a conjugate that can bind 
mitochondria in a stable electrostatic interaction. The AsG component can target 
mitochondria specifically to hepatocytes. Co-internalization of an endosomolytic agent 
co-targeted to hepatocytes through the AsG receptor enhances escape from 
endosomes, facilitating entry of mitochondria into the cytoplasm of cells. The targeted 
mitochondria replicate independent of cell division to restore the complement of 
mitochondria required by the host cells. Normal mitochondria targeted to cells lacking 
mitochondria resulted in restoration of the rates of cell proliferation, and rescue those 
cells from death. The transplanted mitochondria possessed the characteristics of normal 
mitochondrial respiration, and the oxygen consumption rates per cell approached 
normal after mitochondrial transplantation.  
These data represent the first description of targeted introduction of foreign 
mitochondria into recipient cells other by cell fusion. It is also the first description of the 
use of receptors to target organelles to hepatocytes. 
Currently, there is no treatment for mitochondrial dysfunction, and no means to repair or 
replace damaged mitochondria. The data demonstrate a method for mitochondrial 
transplantation, and is potentially curative for diseases caused by hepatic mitochondrial 
damage. Because the liver is the primary target of mitochondrial dysfunction induced by 
drugs/alcohol, in cases of liver failure, transplantation of healthy mitochondria to 
hepatocytes could be a potential treatment. This study forms the scientific basis for a 




functional mitochondria could be transplanted in cells with mitochondrial dysfunction. 
This could provide a generic and safe treatment for the mitochondrial hepatopathies 
where mitochondria renders dysfunctional because of genetic defect in mitochondrial 
DNA or mitochondrial damage is induced. Several nucleoside-based drugs and alcohol 
are known to induce such damage in liver. This therapy would be very helpful where 
use of mitochondrial damaging drugs in inevitable.  
The endosymbiotic theory was first articulated by the Russian botanist Mereschkowski 
in 1905 [354]. Since then it has been modified and revised several times [355, 356]. 
According to this theory, mitochondria originated as free-living proteo-bacteria that were 
taken inside by primitive eukaryotic cell where they developed symbiotic relationship 
later. This study provides evidence in favor of endosymbiosis theory. Successful uptake 
of Fl-AsOR-PL-mitochondrial complex by hepatocytes provides evidence that 






CHAPTER 7: FUTURE DIRECTIONS 
ENHANCED ESCAPE OF AsG-MITOCHONDRIA COMPLEXES FROM 
ENDOSOMES AFTER INTERNALIZATION  
Fl-AsOR-PL-mitochondria complexes exposed to hepatocytes in presence of AsOR-
LLO conjugate leads to facilitate delivery of complex in cytoplasm of the hepatocytes. 
There have been reports that multiple ligands bind to the receptors and are internalized 
together in same endosomes [318]. In this case, both ligands recognize same receptor 
on cells surface, which might lead to competition in binding. Competition is unlikely due 
to the low ratio (1:30::AsOR-LLO conjugate: AsG-mitochondria complex) of AsOR-LLO 
conjugate is added to facilitate the escape of Fl-AsOR-PL-mitochondria complex from 
endosomes. However, in order to eliminate the chances of competition for binding to the 
receptor on cell surface and, improve the escape after internalization from endosomes 
before lysosomal digestion, a ternary complex can be formed by complexing AsOR-LLO 
conjugates directly to mitochondria rather than by delivering them separately by 
separate receptor. It may improve the chances of escape of internalized Fl-AsOR-PL-
mitochondria complexes from endosomes as it would ensure co-uptake and co-
internalization of both Fl-AsOR-PL-mitochondria complexes and AsOR-LLO conjugate 
in same endosomes. Studies on various methods to form such ternary complexes are 
anticipated. Complexes of AsOR-PL to LLO or AsOR to LLO-PL can be formed to make 
a conjugate of AsOR-LLO-PL. Presence of PL in conjugate would provide positive 
charge to the conjugate which would help making stable complexes with mitochondria 




charge interactions. Disulfide cross-linkers can be used to make complexes of LLO with 
AsOR-PL to avoid conformational changes in LLO and allow release of LLO from 
conjugates in reducing environment of endosomes for its membranolytic activity. 
Release of LLO from the AsOR-LLO-PL conjugates could be determined by reduction 
with DTT. Hemolytic assays can be performed with and without DTT at pH 7.4 and pH 
5.6 to determine the membranolytic activity of LLO in AsOR-LLO-PL conjugate. LLO in 
form of AsOR-LLO-PL conjugate is expected to be non-damaging to the membranes till 
it is reduced in reducing environment of endosomes. To determine if AsOR-LLO-PL 
conjugates damage the outer membrane of mitochondria after making complexes with 
mitochondria before internalization, cytochrome c assays can be performed with and 
without DTT at pH 7.4 and pH 5.6. Optimum ratios of AsOR-LLO-PL and AsOR-PL can 
be calculated to make the ternary complex with isolated mitochondria for efficient 
binding to receptors on cell surface and internalization of the ternary complexes as well 
as efficient escape of complexes from the endosomes before lysosomal degradation. 
Increased efficiency of mitochondrial delivery with ternary complexes can be determined 
by comparing mitochondrial delivery to the hepatocytes in presence and absence of 
AsOR-LLO-PL conjugates. Function and stability of targeted mitochondria to 
hepatocytes as a form of ternary complex can be determined by rescuing the 
mitochondria free hepatocytes from cell death in supplement free media and measuring 






CRYOPRESERVATION OF MITOCHONDRIA 
Mitochondria to be used for making complexes with AsG for targeted transplantation to 
hepatocytes should be healthy and functional for successful treatment and rescue of 
cells with damaged mitochondria. Isolation of intact mitochondria from cells is a very 
delicate and time consuming process in which any damage can induce structural 
alterations and functional impairments associated with oxidative phosphorylation. 
Isolation of fresh mitochondria each time before complex formation and internalization 
process causes increased chances of artificial damage induced by repeated technical 
handling. Also assessment of mitochondrial isolation efficiency and stability of isolated 
mitochondria after each isolation process adds to delay in further use of isolated 
mitochondria for targeting to hepatocytes. Delivery of damaged mitochondria to cells will 
not only result into in-effective treatment of mitochondrial disorders of hepatocytes, but it 
can also augment the chances apoptosis in targeted cells because of damaged 
mitochondria. Because mitochondria are fragile and easily deteriorate, to be of practical 
use, the development of a method of cryopreservation of mitochondria would be helpful.  
Isolated mitochondria have to be stored in appropriate media to provide stability to 
mitochondrial membranes and suitable ionic levels for mitochondrial function before use 
[309]. More appropriate storage buffers are required to provide proper environment for 
long-term storage and cryopreservation of mitochondria [357, 358]. If satisfactory 
cryopreservation could be achieved, mitochondria for transplantation could be stored 
and complex formation for targeting to hepatocytes conducted immediately prior to use. 
Studies in this area are planned. Proper conditions of long term storage of isolated 




and biochemical parameters can be obtained in isolated mitochondrial suspensions  
[359] to determine long term stability and efficient function of isolated mitochondria in 
mitochondrial storage buffers. Damage to mitochondrial membrane due to long term 
storage can be determined with cytochrome c assays. Half-life and functional abilities of 
preserved isolated mitochondria in appropriate medium at different temperatures can be 
determined by measuring the damage to isolated mitochondria over time at different 
temperatures using membrane potential determining dyes such as JC-1 [360]. 
Identification of storage conditions and development of method of cryopreservation of 
mitochondria would eliminate the step of assessment of efficiency of mitochondrial 






AsGR-MEDIATED HEALTHY AND FUNCTIONAL MITOCHONDRIA 
DELIVERY TO HEPATOCYTES IN ANIMALS 
Evidence shows that stable complexes of positively charged AsGs and mitochondria 
could be targeted specifically to hepatocytes and endosomolytic agents can facilitate 
escape of targeted mitochondria from endosomes to cytoplasm in cell culture. AsGR-
mediated mitochondria delivery to hepatocytes in vivo would help developing a potential 
method of treatment for hepatic mitochondrial dysfunctional disorders. Rats can be used 
to develop the procedure of delivering mitochondria to hepatocytes in vivo. Studies in 
this area are on-going.  
Huh 7 cells can be used as source of mitochondria since DNA sequence of Huh 7 
mitochondria is distinguishable from rat cell mitochondrial DNA. Complexes of Fl-AsOR-
PL and mitochondria could be injected in a rat tail vein. Since extensive blood supply 
allows liver cells to filter blood off the toxins, we anticipate that blood would carry the 
complexes to liver cells where those could be recognized and internalized by 
hepatocytes.  
Several potential problems are anticipated for the process: 
1. Stability of the complexes in the blood can be affected by different types of serum 
proteins with different sizes and charges [361]. Some positively charged serum 
proteins [362-364] may also compete with the carrier protein for binding to 
mitochondria. Aggregation of complexes might also occur in presence of some 




2. Blood macrophages have been shown to cause poor efficiency of delivery of 
biomolecules to desired tissues [365]. Interactions between macrophages and 
mitochondria complexes could be a potential problem. 
3. Non-specific adherence of mitochondrial complexes to RBCs [366] may hinder 
the uptake of complexes by hepatocytes.  
4. Optimum size of the mitochondrial complexes that could be internalized by 
hepatocytes in vivo will have to be studied [363, 367].  
5. Because of larger size of the complexes, filtration of complexes in alveolar 
capillaries may also hinder the complexes enriched blood to reach hepatocytes 
[364, 368]. 
6. The rat liver sinusoidal (capillaries carrying blood in liver) diameter is 
approximately 5 µm and fenestrae (small pores in endothelial cells that allow for 
rapid exchange of molecules between sinusoid blood vessels and surrounding 
tissue) are approximately 100 nm diameter. Smaller size of fenestrae could 
hinder the delivery of large sized mitochondrial complexes to hepatocytes in vivo. 
7. Kupffer cells (liver macrophages) could engulf the mitochondrial complexes that 
reach the liver and hinder the AsGR mediated uptake of complexes by 
hepatocytes.   
The following are few alternative strategies for above mentioned anticipated problems: 
Mitochondria complexes could be filtered before injecting to obtain a suspension of 




Some types of ultrafine aggregates and carbon particles could inhibit phagocytosis in 
macrophages [369, 370]. Use of these particles might reduce the interactions between 
macrophages and mitochondria complexes. These particles would also increase the 
availability of complexes to hepatocytes by inhibiting Kupffer cells.  
Endothelin is a vasoconstrictor which causes release of calcium by the sarcoplasmic 
reticulum (SR) and results in increased smooth muscle contraction and vasoconstriction 
[371]. Endothelin receptor antagonist can help in inhibition of vasoconstriction and help 
in un-restricted movement of large cargos injected in blood for delivery to liver. Several 
FDA approved endothelin receptor antagonist (ERA) are available like ambrisentan 
(selective for the type A endothelin receptor (ETA) [372]) and bosentan (antagonist of 
endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors [373]). 
These antagonist are also used to treat pulmonary arterial hypertension [374]. These 
ERA could allow the free circulation of complexes in blood and through alveolar 
capillaries as wells as liver sinusoid blood vessels and fenestrae.  
Delivery of Huh 7 mitochondria to hepatocytes could be determined with qPCR, 
electron-microscopy or FISH (fluorescence-based in situ hybridization) assays. 
Localization of protein carriers could be determined by electron microscopy and 
immunohistochemistry. Specific delivery of mitochondria to hepatocytes can be 
determined by measuring the Huh 7 mitochondrial DNA levels in other organs such as 






APPENDIX A: DETERMINATION OF CHANGE IN SIZE OF ASOR AFTER 
ADDING FLUORESCENCE TAGS AND POLY-LYSINE CHAINS BY SDS-
PAGE 
 
AsOR, Fl-AsOR and Fl-AsOR-PL were run on 15% SDS-PAGE and stained with 
Coomassie Brilliant Blue to determine size. SDS-PAGE illustrates that Fl-AsOR is 
slightly larger than AsOR and Fl-AsOR-PL is larger than both AsOR and Fl-AsOR. Data 
show that addition of fluorescence tags and poly-lysine chains to AsOR results in 





APPENDIX B: FLUORESCENCE OF GFP-LABELED MITOCHONDRIA WHILE 
DETERMINING STABILITY OF FL-ASOR-PL- MITOCHONDRIA 
COMPLEXES. 
 
Freshly isolated GFP labeled rat mitochondria were incubated with Fl-AsOR-PL or Fl-
AsOR and repeatedly centrifuged and re-suspended in fresh medium. Fluorescence 
levels of GFP labeled mitochondria at 520 nm were determined with fluorescence levels 
of proteins at 685 nm (Figure 2.7). The data show that GFP-labeled mitochondria 
fluorescence decreased from 25,000 units to 23,000 units after second spin, and 
remained stable thereafter (p<0.01). Fluorescence levels of proteins (Figure 2.7) in 
corresponding spin cycle shows that in contrast to Fl-AsOR, Fl-AsOR-PL remained 






APPENDIX C: DETERMINATION OF STABILITY OF FL-ASOR-PL–
MITOCHONDRIA COMPLEX BY ELECTRON MICROSCOPY  
 
Freshly isolated rat mitochondria were incubated with Fl-AsOR-PL or Fl-AsOR to form 
stable complexes. Complexes were fixed with 4% paraformaldehyde for 10 min, and 
then washed with PBS. Cells were incubated with anti-orosomucoid antibody (Abcam, 
ab88869) for 2 h at 4°C. Goat Anti-Mouse IgG H&L (10nm Gold) (Abcam) secondary 
antibody was added for 1 h. Complexes were washed 3 times with PBS for 5 min each 
and fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, and embedded 
in 3% agarose. Pellets were post fixed in OsO4, dehydrated in ethanol and embedded in 
Poly/Bed 812 (Poly sciences, Inc.). Ultrathin 70 nm sections were mounted on 300 
mesh Cu grids, stained with uranyl acetate and Sat’s lead citrate, and examined with 
Hitachi H-7650 TEM. The data showed that unlike Fl-AsOR (Figure A), Fl-AsOR-PL 





APPENDIX D: DETERMINATION OF UPTAKE OF PROTEINS BY USING 
RADIOACTIVE TAG (125I) 
 
 
AsOR, Fl-AsOR and Fl-AsOR-PL were labeled with Na125I using Pierce™ Iodination 
Beads according to manufacturer’s specification [375] to form 125I-AsOR, 125I-Fl-AsOR 
and 125I-Fl-AsOR-PL. Labeled protein was purified using PD-10 column according to 
manufacturer’s instructions. Uptake assays were performed for 1 h as explained in 
Chapter 2, Methods. After washing extensively with 10 mM EDTA in ice cold PBS, cells 
were collected and radioactivity was measured using gamma counter (Packard gamma 
counter). Non-specific uptake was determined in presence of 100-fold excess of 
unlabeled AsOR, and specific uptake was determined by difference between total and 
non-specific accumulation of radioactivity in cell lysates. The amount of protein 
internalized by cells was calculated using specific activity of 125I labeled protein used 
(cpm/ug). HTC cells (AsGR (-)) were used as negative controls. The data showed that 2 
million Huh 7 cells internalized approximately 0.022 µg of 125I-AsOR, 125I-Fl-AsOR and 




APPENDIX E: DETERMINATION OF UPTAKE OF PROTEINS BY 
FLUORESCENCE 
 
Uptake of Fl-AsOR-PL was performed with Huh 7 and HTC cells as explained in 
Chapter 2, Methods. Cells were collected at 30 min, 45 min and 60 min, and 
fluorescence levels were measured as explained in Chapter 3, Methods. The data 
showed that fluorescence levels increase in Huh 7 cells with time. Addition of excess 
AsOR led to decreased levels of fluorescence in Huh 7 cells at all-time points (p<0.001). 
HTC cells (AsGR (-)) had fluorescence less than 25% of the fluorescence levels in Huh 
7 cells, the levels did not increase with time. This suggests that association of Fl-AsOR-




APPENDIX F: EFFECTS OF AMANTADINE ON MITOCHONDRIAL DNA 
LEVELS AFTER UPTAKE OF FL-ASOR-PL–MITOCHONDRIA COMPLEX. 
 
 
Cells were treated with 20 µM amantadine (Sigma) for 1 h prior and during the uptake 
assay [376]. Uptake assays were performed as explained in Chapter 2, Methods for 2 h. 
Cells were collected to measure mitochondrial DNA levels with qPCR, and compared to 
untreated controls at various time points.  A, HTC mitochondria DNA levels in Huh 7 




of endosomes, and inhibits lysosomal fusion and digestion [240]. Mitochondrial DNA 
levels in Huh 7 cells decreased from 2,000-fold over controls at 6 h to approximately 
800-fold over controls at 24 h after exposure to complexed mitochondria. Amantadine-
treated Huh 7 cells show 7,000-fold increase in mitochondrial DNA over controls at 6 h 
(p<0.04). That level decreased to 2,000-fold over controls at 24 h. Huh 7 cells exposed 
to mitochondria alone did not show any significant levels of mitochondrial DNA. In 
addition, SK Hep1 cells also did not show any significant levels of mitochondrial DNA at 
any time point (Figure B). The data suggest that treatment of cells with amantadine 
inhibited the digestion of internalized mitochondria till amantadine treatment [240]. 










Cells were incubated separately with cell culture media, mitochondria alone, Fl-AsOR-
PL–mitochondria complex, complexed mitochondria and AsOR-LLO conjugate, excess 
AsOR + complexed mitochondria and excess AsOR + complexed mitochondria + 
AsOR-LLO conjugate at 37°C. After 2 h, cells were washed and maintained in 
supplement-free cell culture media. Cells were collected to measure Fl-AsOR-PL levels 





The data showed that fluorescence levels in Huh 7 cells decreased from 10,000 units at 
12 h to 4,000 units at 24 h when incubated with complexed mitochondria. Fluorescence 
levels become barely detectable on 7 d. Co-administration of AsOR-LLO conjugate with 
complexed mitochondria resulted in decrease in fluorescence levels from 30,000 units 
at 12 h to 11,000 units at 10 d, Figure A. Pre-incubation of excess free AsOR resulted in 
no significant levels of fluorescence in Huh 7 cells after exposure to complexed 
mitochondria with and without AsOR-LLO conjugate (Figure A). There were no 
significant fluorescence levels in SK Hep1cells under any condition, at any time point, 
Figure B. Data suggest that fluorescence associated with Huh 7 cells after uptake of 







APPENDIX H: FATE OF MITOCHONDRIAL DNA IN CELLS AFTER UPTAKE 
 
Cells were incubated separately with cell culture media, mitochondria alone, Fl-AsOR-
PL–mitochondria complex, complexed mitochondria and AsOR-LLO conjugate, excess 
AsOR + complexed mitochondria and excess AsOR + complexed mitochondria + 
AsOR-LLO conjugate at 37°C. After 2 h, cells were washed and maintained in 




levels with qPCR and compared to untreated controls at different time points.  A, Huh 7 
cells; B, SK Hep1 cells.  
Mitochondrial DNA levels in Huh 7 cells incubated with complexed mitochondria 
declined from 300-fold over controls at 12 h to undetectable at 24 h. Co-administration 
of AsOR-LLO with complexed mitochondria in Huh 7 cells resulted in 1,250-fold 
mitochondrial DNA over controls at 12 h to less than 400-fold at 24 h and barely 
detectable at 7 d. Pre-incubation of excess free AsOR resulted in no significant levels of 
mitochondrial DNA in Huh 7 cells after exposure to complexed mitochondria with and 
without AsOR-LLO conjugate (Figure A). SK Hep1cells did not show any significant 





APPENDIX I: FATE OF MITOCHONDRIAL DNA IN MITOCHONDRIA FREE 
CELLS AFTER UPTAKE FOR EXTENDED PERIODS OF TIME 
 
Huh 7 mito (-) cells were incubated with complexed HTC mitochondria and AsOR-LLO 
conjugate at 37°C. After 2 h, cells were washed and maintained in supplement-free cell 
culture media. Cells were collected to measure HTC mitochondrial DNA levels by qPCR 
and compared to untreated controls. Data showed that mitochondrial DNA levels were 
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